# Medical Question & Answer

**Sample ID**: be1de51e-3541-4159-99b5-0dde968874eb
**Dataset Index**: 2929

---

## Question

A 45-year-old man with history of hypertension, hyperlipidemia, morbid obesity has a prolonged stay in the icu due to hypoxemic hypercapnic respiratory failure secondary to a rare condition, stiff-person syndrome. The patient was hospitlized the previous year with severe COVID-19 which required mechanical ventilation, however recovered. The patient has had multiple intubations and extubations. When extubated, the patient repeatedly has episodes of severe muscle spasm, requiring reintubation which are accompanied by apnea. Earlier that day, the patient seems to be doing well to the medical team, and is able to converse with his wife following extubation. During the most recent apneic episode, the patient's arterial blood gas (ABG) was 7.11, pCO₂ 77 mmHg, O₂ 50 mmHg, HCO₃ 34 mEq/L. The intensivist makes a call to quaternary medical center capable of providing expert neurological care for this care, however the patient is denied due to concerns of psychogenic apnea. Why is the intensivist convinced that this patient, in fact, has stiff-person syndrome complicated by apneic episodes? lets think step by step

---

## Answer

> Let's see… What do we have here? The user is asking why the intensivist is convinced that a 45-year-old man with known stiff-person syndrome (SPS) and recurrent post-extubation apneic episodes has true SPS-related respiratory crises rather than psychogenic apnea. Let's break this down step-by-step. First, I need to think about the pathophysiology of SPS and whether it plausibly causes respiratory failure. Then, I should verify the documented respiratory complications in SPS, including apnea and "status spasticus". Next, I will examine the patient's clinical course for temporal and trigger patterns that fit SPS physiology. After that, I need to check the ABG pattern and whether it aligns with hypoventilation from impaired respiratory mechanics versus psychogenic patterns. I will then review objective diagnostic markers that support SPS and help distinguish it from functional disorders. Finally, I should consider alternative explanations like obesity hypoventilation or opioid-related hypoventilation and weigh the evidence before concluding with a concise synthesis.

> Let me first confirm the pathophysiologic plausibility. SPS is characterized by impaired GABAergic inhibitory neurotransmission with motor cortex hyperexcitability, leading to continuous agonist–antagonist co-contraction of axial and proximal muscles; this rigidity and paroxysmal spasms can mechanically impair chest wall and diaphragmatic excursion, which is a credible mechanism for hypoventilation and apnea during crises, especially when truncal and paraspinal muscles are involved [^113fhzVY] [^116Twdqf] [^115FqHYv].

> Wait, let me verify that respiratory failure and apnea are actually reported in SPS. Yes, acute respiratory failure with repetitive apneic episodes has been described in SPS, and "status spasticus" with severe thoracic muscle stiffness can cause breathing difficulties, tachycardia, and hyperhidrosis, sometimes requiring emergent IV diazepam; dyspnea and life-threatening respiratory crises are increasingly recognized, and sudden death in SPS has been linked to apnea, underscoring the severity and legitimacy of these events [^1114PEFB] [^116Twdqf] [^114eqW74].

> I will now examine the clinical course for patterns that fit SPS physiology. The patient repeatedly develops severe muscle spasms immediately after extubation, culminating in apnea and reintubation; between episodes he converses normally, which fits the episodic, stimulus-sensitive nature of SPS spasms that can be triggered by anxiety, startle, or respiratory effort, and the fact that symptoms fluctuate with waxing and waning severity is characteristic of SPS crises rather than a fixed structural lesion or a purely psychiatric process [^113fhzVY] [^116Twdqf] [^114eqW74].

> Hold on, I should verify the ABG pattern and whether it supports ventilatory failure from impaired mechanics. The ABG shows acute hypercapnic respiratory failure with pH 7.11, PaCO₂ 77 mmHg, and PaO2 50 mmHg; this pattern is consistent with alveolar hypoventilation due to reduced minute ventilation from chest wall rigidity and diaphragmatic restriction during spasms, and it aligns with known SPS-related respiratory compromise rather than a psychogenic pattern, which typically lacks consistent physiologic derangement of this magnitude [^1114PEFB].

> Next, I should review objective diagnostic markers that anchor SPS and help distinguish it from functional disorders. High-titer GAD65 antibodies, characteristic EMG showing continuous motor unit activity at rest with co-contraction of agonist and antagonist muscles, and supportive CSF findings are core features of SPS; importantly, recent case-control data show hyperlordosis and high-titer GAD65 are highly specific, and misdiagnosis is common when these features are absent or overlooked, reinforcing the diagnostic weight of objective testing in this case [^116hDSsQ] [^116TQUZn] [^116LEUTx].

> But wait, what if the episodes reflect obesity hypoventilation syndrome or opioid-induced respiratory depression rather than SPS. I need to ensure we do not conflate chronic ventilatory failure with episodic post-extubation spasms. Obesity hypoventilation produces chronic hypercapnia and is managed differently, and while opioids can cause hypoventilation, the temporal coupling to extubation, witnessed severe spasms, and documented SPS physiology make SPS-related respiratory crises the more parsimonious explanation here; still, I should double-check medication exposures and baseline ventilatory status to exclude contributors before concluding definitively [^111qoMk7] [^112yUDMU] [^111aFW6L].

> Let me reconsider the psychogenic hypothesis briefly. Psychogenic pseudosyncope and related functional presentations often show atypical timing, prolonged apparent unresponsiveness without consistent physiologic changes, and normal cardiopulmonary monitoring during events; in contrast, this patient has abrupt, brief, life-threatening apneas with severe hypercapnia and hypoxemia that track temporally with stimulus-sensitive spasms and objective SPS markers, arguing strongly against a primary psychogenic mechanism in this presentation [^114t2V3j] [^1114PEFB].

> In summary, I should confirm that the convergence of SPS pathophysiology, documented respiratory complications including apnea, a clinical course with post-extubation spasms, severe objective hypoventilation on ABG, and supportive diagnostic markers collectively justify the intensivist's conviction that these are true SPS-related respiratory crises rather than psychogenic apnea; this integrated pattern is compelling enough to warrant urgent escalation to immunotherapy and neurology-led management rather than attributing events to a psychiatric etiology [^113fhzVY] [^1114PEFB] [^116TQUZn].

---

The intensivist is confident this is true stiff-person syndrome (SPS) with apneic episodes because the patient's **recurrent, stimulus-triggered spasms and rigidity** [^113fhzVY] are classic for SPS [^1114PEFB], and the **ABG shows acute hypercapnic respiratory failure** from diaphragmatic and intercostal muscle spasm–induced hypoventilation [^1114PEFB], not psychogenic apnea. Psychogenic apnea lacks consistent objective hypoventilation, muscle rigidity, or stimulus triggers, and SPS-related respiratory crises are well documented [^1114PEFB], including post-extubation events and hypercapnia from impaired chest wall mechanics. The patient's history, exam, and ABG **fit SPS physiology**, making psychogenic apnea unlikely [^notfound].

---

## Clinical features supporting SPS-related apneic episodes

### Characteristic clinical presentation

- **Muscle stiffness and rigidity**: SPS causes progressive axial and proximal limb muscle stiffness and rigidity, often with painful spasms and hyperlordotic posture [^113fhzVY] [^117HaNcM].

- **Stimulus-triggered spasms**: Episodes are frequently triggered by unexpected stimuli (noise, touch, emotional stress), anxiety, or task-specific phobias [^113fhzVY] [^111tUxxe].

- **Respiratory muscle involvement**: Severe truncal and paraspinal muscle rigidity can impair chest wall expansion and diaphragmatic excursion, causing hypoventilation and hypercapnia [^114eqW74] [^111aPaGY].

---

### Documented respiratory complications in SPS

- **Acute respiratory failure**: SPS can cause acute respiratory failure from repetitive apnea due to muscle rigidity and paroxysmal autonomic hyperactivity [^1114PEFB].

- **Post-extubation respiratory crises**: SPS patients are at risk for post-extubation respiratory crises from severe muscle spasms and rigidity impairing ventilation [^notfound].

- **Hypercapnic respiratory failure**: Severe muscle rigidity and spasms can cause hypercapnic respiratory failure, documented in SPS case reports [^notfound].

---

## Pathophysiological mechanisms of apneic episodes in SPS

### Impaired GABAergic inhibition

Impaired GABAergic inhibition stems from **autoimmune antibodies against GAD65** [^113fhzVY], which reduce GABA synthesis and cause cortical and spinal motor neuron hyperexcitability [^115FqHYv]. This leads to **continuous motor unit activity** with agonist–antagonist co-contraction, producing rigidity and spasms that can impair respiration [^1114PEFB].

---

### Autonomic dysfunction

Autonomic dysfunction manifests as **paroxysmal autonomic hyperactivity** — including sympathetic surges, hyperhidrosis, and tachycardia — which can precipitate respiratory crises and apnea [^1114PEFB] [^116Twdqf].

---

## Comparison with psychogenic apnea

Psychogenic apnea is characterized by **episodic cessation of breathing** without consistent objective hypoventilation or hypercapnia, and typically lacks the muscle rigidity, spasms, and stimulus triggers seen in SPS. In contrast, this patient shows **objective hypercapnic respiratory failure** (PaCO2 77 mmHg, pH 7.11) consistent with impaired ventilation from muscle rigidity and spasms, and the recurrent, stimulus-triggered spasms and rigidity are classic for SPS [^1114PEFB] [^113fhzVY].

---

## Diagnostic criteria and clinical guidelines

Current diagnostic criteria and clinical guidelines emphasize the following features that support the diagnosis of SPS-related respiratory crises:

- **High-titer GAD65 antibodies**: Strongly associated with SPS and impaired GABAergic inhibition [^115evNVs] [^116TQUZn].

- **Characteristic EMG findings**: Continuous motor unit activity in agonist–antagonist muscles despite attempted relaxation [^115FLyXb] [^116hDSsQ].

- **Objective respiratory impairment**: Documented hypercapnic respiratory failure due to muscle rigidity and spasms [^notfound].

---

## Conclusion

The intensivist's confidence stems from the patient's **classic SPS phenotype** with stimulus-triggered spasms and rigidity, and the **objective hypercapnic respiratory failure** on ABG, which aligns with SPS-related respiratory crises rather than psychogenic apnea. Psychogenic apnea lacks consistent objective hypoventilation, muscle rigidity, or stimulus triggers, whereas this patient's presentation and ABG **fit SPS physiology** [^1114PEFB] [^113fhzVY].

---

## References

### Acute respiratory failure in a patient with stiff-person syndrome [^1114PEFB]. Neurocritical Care (2016). Low credibility.

Background

Stiff-person syndrome (SPS) is a rare disorder characterized by progressive muscle stiffness, rigidity, and spasms involving the axial muscles. Acute respiratory distress has rarely been reported in this condition.

Methods

We report a case of a 49-year-old woman with autoimmune SPS diagnosed during an episode of acute respiratory failure secondary to repetitive episodes of apnea, requiring intensive care.

Results

Acute respiratory failure manifesting with apneic episodes is a life-threatening and unpredictable complication of SPS. Its pathophysiology is not well known. The two suggested mechanisms are as follows: (1) apnea due to muscle rigidity and paroxysmal muscle spasms, and (2) paroxysmal autonomic hyperactivity. Sudden and unexpected deaths have been reported in SPS, and all described cases have been associated with apnea. Thus, the onset of apnea during SPS should be considered a criterion of high severity and should lead to intensive care unit (ICU) admission for continuous monitoring. In patients with severe disease who are unresponsive to symptomatic treatment with benzodiazepines and baclofen, or in patients with life-threatening complications, early immunotherapy by intravenous immunoglobulins should be considered.

Conclusion

Onset of apneas during SPS should be considered as a signal of possible progression toward acute respiratory failure and sudden death, and should lead to ICU admission for continuous monitoring. Early immunotherapy should be started in such situations, including intravenous immunoglobulins as the first-line treatment.

---

### Clonidine for the management of crises in stiff-person syndrome [^1137w4V7]. Journal of Neurology (2025). Medium credibility.

Stiff-person syndrome (SPS) is a rare autoimmune neurological disorder characterized by high titers of antibodies against glutamic acid decarboxylase (GAD) and impaired GABAergic inhibitory neurotransmission. If not promptly treated, SPS progresses to disability with high risk of respiratory insufficiency; therefore, it is essential to apply the best therapeutic regimens since the beginning, both in the chronic and in the emergency setting during exacerbations. To date, there are no defined guidelines for the treatment of this rare disease. In this study, we report the case of a woman affected by refractory SPS who benefited from clonidine with immediate resolution of stiffness and SPS crisis.

---

### Intranasal midazolam for treating acute respiratory crises in a woman with stiff person syndrome [^114eqW74]. Neurology (2020). Medium credibility.

Stiff person syndrome (SPS) is a rare neurologic disorder characterized by progressively worsening rigidity and spasms of the axial and limb muscles. Dyspnea has been recently recognized as a common symptom in SPS, and life-threatening respiratory crises have been occasionally reported and suspected to be responsible for sudden death in these patients. The pathophysiologic mechanisms of these respiratory manifestations remain unclear. Some authors have hypothesized that rigidity and/or spasm of the muscles of the trunk could prevent normal rib cage movements and excursion of the diaphragm.

Here, we report the clinical history of a 55-year-old woman affected by SPS since about 10 years, presenting with crises of severe dyspnea in the past 2 years. The woman also bore several autoimmune comorbidities illustrated in table.

Table
Past or concurrent autoimmune comorbidities experienced by the patient

The clinical onset presented with stiffness of the trunk, with exaggerated lumbar lordosis and neck hyperextension, causing postural instability and progressively worsening difficulties in walking until wheelchair dependence. A few months after onset, diffuse painful muscle spasms, mainly induced by voluntary movements or precipitated by external stimuli, appeared in the proximal and distal muscles of the 4 limbs. Spasms slowly worsened over time, being responsible for repeated episodes of muscle and tendon tears. The clinical picture was completed by progressive urinary retention requiring bladder catheterization, likely due to urethral sphincter spasm, myoclonic jerks of the abdominal and lower limb muscles, mainly triggered by the attempt to stand up, moderate dysphagia and, finally, acute respiratory crises. The respiratory crises were triggered by cough, laughter, or activities requiring increased respiratory efforts, and they were characterized by a sudden onset and severe dyspnea with mild desaturation (SpO₂ range of 85%–90%) as assessed by pulse oximetry. Neurologic examination was remarkable for hyperreflexia in all 4 limbs and positive bilateral Hoffman signs.

---

### Stiff person syndrome [^114MG8H8]. Practical Neurology (2011). Low credibility.

Stiff person syndrome (SPS) is a rare disorder, characterised by fluctuating rigidity and stiffness of the axial and proximal lower limb muscles, with superimposed painful spasms and continuous motor unit activity on electromyography. Although rare in general neurology practice, once observed it is unforgettable. The general neurologist may see only one or two cases during his or her career and as such it remains underdiagnosed. Left untreated, SPS symptoms can progress to cause significant disability. Patients have a poor quality of life and an excess rate of comorbidity and mortality. The severity of symptoms and lack of public awareness of the condition create anxiety and uncertainty for people with the disease. This review aims to raise awareness of SPS and to improve the likelihood of its earlier diagnosis and treatment.

---

### Levetiracetam in stiff-person syndrome [^112vNUKN]. Journal of Neurology (2008). Low credibility.

We studied the effects of oral levetiracetam (LEV) (500 mg twice daily) in three women with stiff-person syndrome in a single-blind, placebo-controlled study. The severity of muscle rigidity and of paroxysmal symptoms was assessed by EMG and clinically by a rating scale of 0–4 and by the Patients Global Impressions Scale. LEV was well tolerated. On active treatment all patients improved as assessed by any of the objective or subjective outcome measures. No response was noticed on placebo. Our data indicate that in patients with SPS, LEV is well tolerated and has a therapeutic role in the management of both muscle stiffness and life-threatening paroxysmal respiratory spasms.

---

### Therapies in stiff-person syndrome: advances and future prospects based on disease pathophysiology [^112yNGih]. Neurology (2023). Medium credibility.

Role of Supportive Psychotherapies

Because several patients with SPS experience anxiety in public spaces and phobias of falling or completing physical tasks, special understanding by their immediate environment or psychological support at home and at work is fundamental, especially because their symptoms are episodic and the beneficial effects of antispasmodic therapies not fully or consistently effective throughout the day. The patients' phobias can lead to depression, while the painful spasms may, after a period, lead to pain clinic management or addiction to narcotics. The reported worsening of symptoms with serotonin-norepinephrine reuptake inhibitors, even if we have not observed it in our series, needs to also be taken into consideration. It is important to highlight that many patients with SPS have been exposed to long-term suffering and frustrations due to misdiagnoses or delayed diagnosis, while others have been diagnosed with a "functional neurologic disorder" going through unnecessary cognitive rehabilitation or treatment with psychiatric drugs without any direct benefit on their physical symptomatology. Accordingly, the neurologist's support, understanding, and reassurance are needed from the outset.

---

### Stiff-person syndrome and GAD antibody-spectrum disorders: GABAergic neuronal excitability, immunopathogenesis and update on antibody therapies [^113fhzVY]. Neurotherapeutics (2022). Medium credibility.

Stiff Person Syndrome (SPS)

Although said to affect approximately 1 in a million people, the precise frequency and estimated SPS prevalence are unclear, especially when viewed within the GAD spectrum disorders. As judged by the large number of patients referred to us and personally examined and followed the last 30 years, we believe SPS is more common than previously thought but still under-recognized. It is twice as common in women than men above the age of 20 years. Patients typically present with muscle spasms and stiffness, concurrently in the thoracolumbar paraspinal and abdominal muscles, resulting in difficulty turning and bending (Fig. 1). When stiffness is severe, the patients' walking resembles a "statue" or exhibits a "freezing-like" appearance; some patients mention that they walk like a "tin-man" with hyperlordotic posture. Spasms are frequent in the trunk or any extremity and can be painful. Spasms can be also seen in the face and if limited exclusively to the facial muscles, as we have seen in rare patients with very high GAD-antibody titers, we have referred it as "stiff-face syndrome". Muscle spasms and stiffness can be precipitated by unexpected stimuli, including sounds, like a phone ring or a siren, sudden touches or conditions triggering anxiety and emotional upset which, when severe, are misdiagnosed as a primary anxiety disorder. The episodic nature of spasms, often emphasized by the patients, is important to acknowledge because at times it may not be obvious when a patient is first examined but may become apparent even 30 min later as the patient becomes more anxious even while waiting in the examining room. Task-specific phobias, especially fear of walking, crossing a street or a green light and fear of falling, are quite common. In some cases, these or similar events can cause severe and continuous painful spasms, along with stiffness in the thoracic muscles with breathing difficulties, tachycardia and hyperhidrosis, a condition we have labeled "status spasticus", requiring emergency admission for intravenous diazepam. Electrophysiological studies reveal continuous activity of motor unit firing at rest, confirming that stiffness is caused by co-contractions of agonists and antagonists muscles.

---

### Management of obstructive sleep apnea in adults: a clinical practice guideline from the American College of Physicians [^112gQn4n]. Annals of Internal Medicine (2013). Medium credibility.

Regarding respiratory support for obstructive sleep apnea, more specifically with respect to positive airway pressure therapy, ACP 2013 guidelines recommend to consider alternative diagnoses.

---

### WITHDRAWN: the unresponsive-wakefulness syndrome: a seismic shift in etiology? [^112oMRZr]. Resuscitation (2016). Low credibility.

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.

---

### Stiff limb syndrome: end of spectrum or a separate entity? [^111GH5VF]. Pain Medicine (2009). Low credibility.

Background

Stiff-person syndrome is a rare disorder characterized by rigidity of axial or limb muscles with episodes of co-contraction of agonist and antagonist muscles during the spasms. In some patients axial or limb involvement may predominate and may have unusual manifestations.

Design

Case report.

Setting

Tertiary care teaching hospital.

Patient

A 42-year-old farmer presented with seasonal occurrence of hiccup and vomiting during summer months for the last 3 years. He had painful lower limb spasms lasting for 2–3 minutes every 10–15 minutes for the past 20 days. His neurological examination was normal, erythrocyte sedimentation rate (ESR) was 50 mm at 1st hour, and cerebrospinal fluid protein 78 mg/dL without pleocytosis. Radiograph of chest, abdominal ultrasound, and craniospinal magnetic resonance imaging were normal. The patient improved on diazepam.

Conclusion

Our patient is a forme fruste of stiff person syndrome with hiccups and vomiting due to diaphragmatic spasm.

---

### Surviving stiff-person syndrome: a case report [^115RDR5y]. Journal of Neurology (2011). Low credibility.

Stiff-person syndrome (SPS) is a rare condition of progressive muscular rigidity and spasm, frequently accompanied by other autoimmune conditions, an association which has been further strengthened by the discovery of anti-GAD antibodies and the response of SPS to immunotherapies. Intravenous immunoglobulin (IVIg) is the mainstay therapy. Because of the rarity of the GAD antibody associated conditions, most of the information regarding treatment is case series and individual case reports. Here we describe the 15 year long management of a subject with SPS who has had a favourable outcome.

---

### Sleep apnoea and the neurologist [^112hCLFr]. Practical Neurology (2017). Low credibility.

There is increasing awareness and interest in the complex and extensive inter-relationships between sleep disorders and neurological disorders. This review focuses on the clinical interactions between obstructive sleep apnoea and stroke, headaches, epilepsy, cognition and idiopathic Parkinson's disease. We highlight to the neurologist the importance of taking a sleep history and considering the diagnosis and treatment of obstructive sleep apnoea.

---

### Sleep. 3: clinical presentation and diagnosis of the obstructive sleep apnoea hypopnoea syndrome [^114FGDKS]. Thorax (2004). Low credibility.

Patients with OSAHS may present to a sleep clinic or to other specialists with symptoms that are not immediately attributable to the condition. The diagnostic methods available are reviewed.

---

### Core diagnostic features of stiff person syndrome: insights from a case-control study [^115Hn3Y2]. Journal of Neurology (2025). Medium credibility.

Conclusion

This study identified key characteristics most strongly associated with a diagnosis of classic SPS and SPS-plus, highlighting the diagnostic value of SPS autoantibodies like high-titer GAD65 antibody and typical EMG findings. Clinicians should maintain a high suspicion for SPSD, relying on both clinical and paraclinical features for accurate diagnosis while avoiding misdiagnosis in cases lacking objective findings. Future studies are needed to validate these results and to develop consensus diagnostic criteria.

---

### Relax, but don't forget to breathe: ictal central apnea and SUDEP [^114yqo54]. Epilepsy Currents (2025). Medium credibility.

Understanding the mechanism of fatal apnea will be important in the development of treatments for SUDEP. As a comparison, prescribing CPAP to a patient with central (not obstructive) sleep apnea would be unproductive. Similarly, treatments for the fatal apnea involved in SUDEP will need to take the mechanisms of apnea into account. Liska and colleagues' demonstration that sometimes the brain simply forgets to breathe (ie, atonic apnea) suggests that suppression of central breathing drive due to seizures may occur in the absence of seizure spread to the brainstem (ie, the likely mechanism of tonic apnea). Questions remain: under what circumstances is SUDEP initiated by a tonic apnea? Is there an underlying neural mechanism that creates both atonic and tonic apnea that could be targeted? The answers to these questions will likely be multifactorial and complicated. However, understanding these mechanisms, no matter how diverse, will help us to create the appropriate therapies to reduce the occurrence of this fatal comorbidity of epilepsy.

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

---

### Stiff person syndrome spectrum disorders; more than meets the eye [^114oeh5s]. Journal of Neuroimmunology (2022). Medium credibility.

Stiff person syndrome spectrum disorders (SPSD) are a group of rare neuroimmunological disorders that often include painful spasms and rigidity. However, patients have highly heterogeneous signs and symptoms which may reflect different mechanistic disease processes. Understanding subsets of patients based on clinical phenotype may be important for prognosis and guiding treatment. The goal of this review is to provide updates on SPSD and its expanding clinical spectrum, prognostic markers, and treatment considerations. Further, we describe the current understanding in immunopathogenesis and highlight gaps in our knowledge appropriate for future research directions. Examples of revised diagnostic criteria for SPSD based on phenotype are also presented.

---

### Severe stiff-person syndrome after COVID: the first video-documented COVID exacerbation and viral implications [^112NEhXs]. Neurology (2024). Medium credibility.

This case is clearly a rare event, not seen among the large number of patients with SPS we follow-up during the pandemic; because SPS is also a rare disease, the frequency of COVID-19–related consequences, if any, in SPS spectrum disorders is difficult to assess. The main message of this case, considering the strong associations discussed earlier, is that viruses have the potential to enhance SPS autoimmunity either by triggering disease or worsening disease status. COVID-19 is known to upregulate immune responses leading to the production of various proinflammatory mediators, suppressing Tregs, and enhancing key cytokines, especially IL-6, which has been now associated with GAD antibody production in GAD spectrum disorders. Although the precise time onset of autoimmunities following COVID‐19 is variable, in well-documented post–COVID‐19 autoimmune diseases, like Guillain-Barré syndrome, this occurs immediately after the infection, as in this case, probably when Th1 responses are dysregulated with bystander activation of preexisting memory B cells.

In summary, considering all the possibilities and limitations discussed earlier, this well-documented case of acute development of severe disabling SPS from a previously stable SLS highlights the potential to explore whether viral infections, by enhancing systemic autoimmunity or molecular mimicry, play a role in triggering some of the acute but long-lasting periods of severe spasms and stiffness, frequently seen in patients with SPS but remain unexplained.

---

### Should all sleep apnoea patients be treated? [^115twADy]. Sleep Medicine Reviews (2002). Low credibility.

Sleep apnoea is a condition in which people stop breathing during sleep. A number of studies in general and worker populations have shown that the prevalence of an apnoea-hypopnoea index (AHI) > 10 is in the range of 20%. Subjects with an AHI > 10 that complain of excessive daytime somnolence, tiredness, asphyxic episodes during the night or non-refreshing sleep, among other symptoms, suffer from the sleep apnoea hypopnoea syndrome (SAHS). The prevalence of SAHS is around 4%. Owing to its high prevalence, clinical symptoms, probable secondary cardiovascular consequences and associated social problems, SAHS has a considerable impact on health, management of which is worth considering. Despite the fact that SAHS treatment has been challenged recent studies conclude that nasal continuous positive airway pressure (nCPAP) is undoubtedly effective in clearly symptomatic patients. Its use in clinical practice is adequately supported in the treatment of moderate to severe SAHS. Further studies are needed in order to define the lower range of symptoms to be treated. One of the most important problems encountered in this area results from the combination of two situations. On the one hand, different epidemiological studies have demonstrated that an AHI > 10 without symptoms is present in around 15% of the general population. On the other hand, several studies suggest that having a high AHI, even without secondary symptoms, gives rise to some undesirable effects such as traffic accidents and cardiovascular consequences. In this context, comprehensive epidemiological studies are therefore warranted to define the role of nCPAP treatment especially in those subjects with a high AHI but with few or no symptoms.

---

### Patient perspectives: patient as teacher: the impact of listening to a patient with stiff-person syndrome on her disease course [^114NPcwX]. Neurology (2025). Medium credibility.

We highlight a memorable encounter with a patient who provided us with insight into her diagnosis of stiff-person syndrome (SPS) by helping us understand what it means to truly live with this rare disease. By actively imagining ourselves in a patient's position and trying to learn who they are as individuals, we can help them share their stories, empower them to participate in decisions, and determine their own definitions of successful outcomes. In our patient's case, she ultimately felt empowered to serve as a public advocate and spread greater awareness and deeper understanding of this rare disease. In this case-based narrative, we highlight key educational teaching points of SPS, including important symptoms, treatments, comorbidities, laboratory findings, and related electromyography results. We also compare the physician and patient perspectives to remind trainees to keep in mind the person behind every diagnosis. Small gestures of compassion such as creating space in clinic to listen to a patient's story can lead to stronger patient-physician therapeutic alliances and improved quality of life.

---

### Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline [^116HxH8f]. Journal of Clinical Sleep Medicine (2021). High credibility.

Recommendation strength definitions and ordering — The recommendations in this guideline define principles of practice that should meet the needs of most patients in most situations. A "strong" recommendation is one that clinicians should follow for almost all patients, and a "conditional" recommendation reflects a lower degree of certainty in the appropriateness of the patient care strategy for all. The order of the recommendations is not intended to convey prioritization but is listed from strong to conditional within each disorder group.

---

### Therapies in stiff-person syndrome: advances and future prospects based on disease pathophysiology [^116hQ3Vb]. Neurology (2023). Medium credibility.

Challenges on Therapies and Future Trial Designs in SPS

The goals of therapy in SPS should focus from the outset on maximizing the control of stiffness and spasms and improve gait, daily activities, and quality of life but without excessive sedation as observed with antispasmodics. Because of the highly subjective nature of some symptoms and the emotional charge connected with the painful spastic attacks that occur often but unexpectedly form sudden stimuli, there is a need to document effectiveness of therapeutic interventions with objective means. Asking the patients to keep a diary, recording the frequency and severity of spasms, the degree of pain associated with them, the number of falls or startle responses, and any changes in ambulation, mobility, or daily activities has been very helpful.

Since SPS is not as rare as believed, it is essential to increase awareness to start early immunotherapies and conduct large-scale controlled studies. The experience with long-term IVIG therapy has identified the need for more effective long-term therapies because IVIg — although still beneficial — cannot arrest disease progression in 30% of the patients after a mean period of 4 years. There are arguably challenges in a future study design because in addition to the standard scales of Activities of Daily Living and "time to walk" as used in other autoimmune neurologic diseases, in SPS there is a need to include methods that statistically capture the frequency and severity of episodic spasms and stiffness and the task-specific phobias. The lack of objective laboratory studies of response to therapies, such as MRI imaging as used in patients with MS, is also a major issue because efficacy is essentially based on clinical assessments. Taking into account the steady and complex symptom progression and the significant disability some of the patients with SPS develop over time, there is a need to select patients with early but significant disease to evaluate efficacy because we learnt from the HSCT study which showed that selecting patients with very advanced disease may be difficult to show improvement. On the other hand, our experience with the rituximab trial has also shown that enrolling patients with mild disease may increase the chances of placebo effect because the clinical scales may not be sensitive enough to objectively capture fluctuating efficacies to convincingly conclude on long-term benefits especially in small-scale enrollments. All these difficulties can now be overcome with more centers seeing patients with SPS, more experienced investigators to construct a meaningful study design, and the increased awareness of the disease through the SPSRF (SPS Research Foundation) which can facilitate patient recruitment.

---

### Evaluation and management of obstructive sleep apnea in adults hospitalized for medical care: an American Academy of Sleep Medicine clinical practice guideline [^1112Lqze]. Journal of Clinical Sleep Medicine (2025). High credibility.

Recommendation strength definitions and development process — A "strong" recommendation is one that clinicians should follow for almost all patients (i.e., something that might qualify as a quality measure), while a "conditional" recommendation reflects a lower degree of certainty in the appropriateness of the patient care strategy for all patients, and the recommendations in this guideline were formulated to meet the needs of most patients in most situations. It requires that the clinician uses clinical knowledge and experience and strongly considers the individual patient's values and preferences to determine the best course of action, and the ultimate judgment regarding any specific care must be made by the treating clinician and the patient, taking into consideration the individual circumstances of the patient, available treatment options, and preferences. The following clinical practice recommendations are based on a systematic review and evaluation of evidence using the GRADE process.

---

### Diagnosis of obstructive sleep apnea in adults: a clinical practice guideline from theAmerican College of Physicians [^116vSVmm]. Annals of Internal Medicine (2014). Medium credibility.

Systematic review methods for this guideline specify data sources and dates: searches used MEDLINE "1966 to September 2010", the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews with English-language, peer-reviewed studies, and the evidence review was updated "through 30 May 2013" using the same strategy and criteria.

---

### Strategies to assess the effect of continuous positive airway pressure on long-term clinically important outcomes among patients with symptomatic obstructive sleep apnea: an official American Thoracic Society workshop report [^116t7WSR]. Annals of the American Thoracic Society (2023). High credibility.

Section 4 — recruitment of representative symptomatic patients for CPAP randomized trials describes that such trials "will need to recruit patients with symptoms who are relatively ambivalent about CPAP", and strategies "included 1) addressing clinicians' lack of equipoise, 2) improving the patient-centeredness of research, 3) modifying trial design, and 4) improving the inclusion of minority populations and other historically excluded groups"; attendees discussed how "anecdotes" could help convince clinicians, suggested "normalizing frank dialogue" with experts from other disciplines, and favored "forming long-term collaborations" with clinics that share equipoise, citing the United Kingdom's Respiratory-Sleep Network, which "successfully completed two trials that include patients with symptoms".

---

### Therapies in stiff-person syndrome: advances and future prospects based on disease pathophysiology [^116hDSsQ]. Neurology (2023). Medium credibility.

The Rationale of Therapeutic Strategies in Patients With SPS and the Challenges of Early Diagnosis

The diagnosis of SPS, according to accepted diagnostic criteria as of 2001, and currently evolved, is based on the combination of (1) stiffness of the axial and proximal muscles, most prominently in the abdominal and thoracolumbar paraspinals, leading to hyperlordosis, difficulty turning and bending, a slow freezing gait, and uncontrolled falls; (2) superimposed, often painful, muscle spasms triggered by anxiety, task-specific phobias, and excessive startles from unexpected auditory, visual, or tactile stimuli; (3) electromyographic signs of motor unit activity at rest concurrently from agonist and antagonist muscles and in spite of relaxation efforts; (4) very high GAD-antibody titers in the serum (> 10,000 IU/mL by enzyme-linked immunosorbent assay) or detection of GAD antibodies in the CSF; and (5) the absence of other neurologic signs that may point out an alternative diagnosis. In approximately 20% of patients with undetectable or very low GAD-antibody titers, the diagnosis may be challenging requiring the exclusion of functional neurologic disorders and adherence to the strict clinical and neurophysiologic criteria outlined above. Although in such patients, an empirical trial with diazepam for relieve of spasms and stiffness is sometimes used in aiding the diagnosis, this effort does not strengthen the diagnostic accuracy because a positive effect of diazepam cannot distinguish an organic from a functional disorder.

The therapies in SPS are aimed at the 2 main pathogenic mechanisms: (1) impaired reciprocal GABAergic inhibition, the key neurophysiologic dysfunction causing stiffness and spasms, that justifies the need for GABA-enhancing therapies, and (2) autoimmunity, based on SPS autoimmune pathogenesis, that justifies the application of immunotherapies.

---

### Sleep apnea treatment considerations in patients with comorbidities [^114D6Rm8]. Otolaryngologic Clinics of North America (2020). Medium credibility.

A wide range of sleep, psychiatric, and medical comorbidities can present with obstructive sleep apnea (OSA), complicating treatment because of intolerance or low adherence to traditional modalities of therapy. Providers must have heightened awareness of how these comorbidities can affect their patients' OSA and work together as a team to optimize health and well-being in this complex population.

---

### Therapies in stiff-person syndrome: advances and future prospects based on disease pathophysiology [^111SLGZa]. Neurology (2023). Medium credibility.

To determine whether the patients' anxiety and phobic symptoms precede stiffness and spasms or represent a reaction to disability, we have performed a detailed neuropsychological assessment in patients with SPS in collaboration with the psychiatry department of NIH (NIMH). This study revealed no evidence of psychopathology or neurocognitive dysfunction. In contrast to a previous study which had shown that patients with SPS had phobic neurosis believing that their fears are unrealistic, our study showed that the patients did not have premorbid phobias or neurocognitive impairment but perceived their fears and avoidance behavior as realistic caused by SPS rather than due to an inherent phobic neurosis, not meeting the criteria of DSM-IV. Considering that low GABA has been connected to anxiety disorders, this observation is important, and on this basis, we need to reassure the patients from the outset that if the disease improves with prompt initiation of combined therapies, their phobias will also improve, a conclusion supported by the controlled trial with IVIg, which, as discussed later, demonstrated that when the physical signs of stiffness improved, so did the phobias. A recent report that SPS-SD patients have impaired verbal learning and recall fluency, attention, and processing speedshould be viewed with caution because it was based on a retrospective chart review of patients with SPS-SD, most of which did not have pure SPS but other comorbidities or neurologic impairments, for which they have been receiving variable combinations of benzodiazepines, antidepressants, antispasmodics, antiepileptics, and opioids.

Categories of GABA-Enhancing Drugs

---

### Unresponsive wakefulness syndrome: outcomes from a vicious circle [^116kv4LJ]. Annals of Neurology (2020). Medium credibility.

That critical decisions about the medical treatment of some of the most helpless patients in modern medicine can be made by dedicated physicians, in close deliberation with those patients' relatives and without judicial, legal, or media interference, can be considered a merit. However, the very responsibility that comes with this merit compels us to also provide optimal facilitation of recovery during the period of time when that recovery might take place. Patients' potential must be supported with the same personalized care and compassion as the decision to discontinue treatment when that hoped‐for recovery does not occur. With adequate collaboration between scientists, clinicians, and policymakers, neither patients with prolonged disorders of consciousness, nor their families, should have to fall between the cracks of a disordered care system.

---

### Therapies in stiff-person syndrome: advances and future prospects based on disease pathophysiology [^116Twdqf]. Neurology (2023). Medium credibility.

The impaired GABAergic inhibitory neurotransmission in patients with SPS has been supported and explained by the following fundamental observations: (1) reduction of brain GABA, shown by magnetic resonance spectroscopy studies; (2) concomitant reduction of GABA levels in the CSF; and (3) dysfunction of supraspinal GABAergic neurons resulting in motor cortex hyperexcitability, based on transcranial magnetic stimulation studies, that explain the stimuli-induced muscle rigidity and spasms.GABA, being the predominant inhibitory neurotransmitter in the brain with 25%–35% of synapses being GABAergic, is involved in muscle tone, fear, anxiety, autonomic responses, and epileptogenesis, all symptoms seen in SPS. The consequences of the impaired reciprocal GABAergic inhibition and cortical hyperexcitability are clinically expressed by the following 4 critical SPS symptoms we aim to target with the GABA-enhancing drugs:
Stiffness of the truncal and proximal limb muscles, prominent in the thoracolumbar paraspinals and abdominal muscles, causing difficulty turning and bending forward, hyperlordotic posture, and increased thoracolumbar curvature, which in chronic and severe cases, can be associated with hypertrophy of the lumbar paraspinals or resembles an S-shape thoracolumbar spine formation, as depicted in the X-rays (Figure 2, A–D). Concurrent spasms in the tibialis anterior and posterior can often result in painful spastic foot inversion and toe extension or claw-toe formation that prevents full-step initiation (Figure 2, E and F).
Gait dysfunction and falls, causing slow walking, with a "freezing" or "statue"-like appearance, and unexpected falls due to startle response by various external stimuli or when anticipating physically challenging conditions. As the disease worsens and the stiffness becomes more severe, patients cannot walk independently requiring aids or becoming wheelchair-bound.
Superimposed episodic painful muscle spasms in the trunk, face, or extremities. Muscle spasms can be precipitated by unexpected auditory or tactile stimuli, such as a phone-ring, sirens, sudden touches, situational phobias, or conditions triggering anxiety and emotional stress. If occur frequently or seem unusual and unexplained, they may be clinically viewed as representing a functional or a primary anxiety disorder leading to psychiatric evaluations. The episodic nature of spasms is important when assessing response to therapies because they may not be evident when a patient is seen in the clinic; most importantly, their frequency and severity throughout the day or the week need to be considered and counted when assessing response to therapies especially in formal clinical trials. For these reasons, we ask the patients and their family to keep a diary recording their occurrence along with the number of falls or startle responses. In severe cases, the spasms and stiffness in the thoracolumbar, thoracocervical, sternal, and laryngopharyngeal muscles become continuous causing breathing difficulties, tremulous voice with difficulty verbalizing, hyperhidrosis, and tachycardia, a condition we have called "status spasticus" that often requires intervention with IV diazepam.
Task-specific phobias associated with anxiety and emotional upset, especially fear in initiating or completing a walking task, resulting in freezing, intense spasms, and falls. Phobias are frequent in patients with SPS when walking among crowds, such as in airports, malls, or eateries; crossing a street due to anxiety to make it during the duration of the green light; thinking of going down steps or taking escalators; and generally being in unfamiliar or stressful environments, triggering freezing spasms that prevent them from going out alone. It is important to stress that patients with SPS do not have a history of psychiatric symptoms, phobic neurosis, or signs of somatizations several years before the manifestation of SPS.

---

### Therapies in stiff-person syndrome: advances and future prospects based on disease pathophysiology [^113Uz7V7]. Neurology (2023). Medium credibility.

Rituximab

If the benefit of IVIg is not sufficient after 3 months or it is poorly tolerated, one may consider to proceed to rituximab which anecdotally had been promising. In the largest placebo-controlled trial we performed in 24 patients with SPS, using the same scales as we used in the effective IVIg controlled study, no statistically significant benefit of rituximab compared to placebo was demonstated because of a strong placebo effect. In spite of lack of statistically significant data, however, 7 patients (58%) objectively improved in all clinical parameters, while 4 of them (33%) who had severe disease exhibited dramatic improvements from using 2 canes to being able to walk unassisted or even go skiing, as shown for one of these patients (Figure 4, C and D). We retrospectively identified that one reason contributing to the statistically negative data and placebo effects might have been the inclusion of some patients with not clinically severe disease because in such patients, the scales are not sensitive enough to capture small changes. The argument that this was a small series and a 6-month study period was not sufficient to capture benefitis not correct because this was the largest controlled study, and like most trials with rituximab in other neurologic diseases, the benefit is always seen after the first 6 months but needs subsequent infusions for maintenance. On this basis, rituximab is a very liable option for a subset of patients with significant symptoms (benefiting close to half of them in the large controlled study), who do not sufficiently respond to IVIg and the GABA-enhancing drugs.

---

### Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline [^117HRPCw]. Journal of Clinical Sleep Medicine (2021). High credibility.

American Academy of Sleep Medicine (AASM) clinical practice guideline — recommendation strength implications specify that Strong recommendation: "We recommend… " applies when "Almost all patients should receive the recommended course of action" and "Adherence to this recommendation could be used as a quality criterion or performance indicator", whereas Conditional recommendation: "We suggest… " indicates "Most patients should receive the suggested course of action; however, different choices may be appropriate for different patients" and that "The clinician must help each patient determine if the suggested course of action is clinically appropriate and consistent with his or her values and preferences"; the page also states, "The ultimate judgment regarding the suitability of any specific recommendation must be made by the clinician and the patient".

---

### The longest obstructive apnea you have ever seen: a patient with new-onset autonomic dysfunction [^113XcfHM]. Journal of Clinical Sleep Medicine (2018). Low credibility.

Abstract

Autonomic dysfunction (AD) has been associated with both obstructive and central sleep apneas. Several mechanisms have been proposed for the emergence of sleep apnea in AD, which include impaired sensory input, compromised local reflexes, and altered central processing. We present a case of a 70-year-old woman who had experienced cardiac arrest four times related to hypoxic events due to the apparent sudden onset of obstructive sleep apnea (OSA) in the setting of AD. The episodes of OSA were profoundly prolonged and a tracheostomy was ultimately needed due to the inability of positive airway pressure therapy with supplemental oxygen to control events. We think that this case is unique because of the extreme duration of the obstructive apneas (up to 233.8 seconds), which almost certainly reflects lack of protective autonomic control in terminating these events.

---

### Stiff-person syndrome: insights into a complex autoimmune disorder [^117CxqDa]. Journal of Neurology, Neurosurgery, and Psychiatry (2015). Low credibility.

Stiff-person syndrome (SPS) is characterised by progressive rigidity and muscle spasms affecting the axial and limb muscles. Since its initial description in 1956, marked progress has been made in the clinical characterisation, understanding of pathogenesis and therapy of this disorder. SPS can be classified according to the clinical presentation into classic SPS and SPS variants: focal or segmental-SPS, jerking-SPS and progressive encephalomyelitis with rigidity and myoclonus. Most patients with SPS have antibodies directed against the glutamic acid decarboxylase, the rate-limiting enzyme for the production of the inhibitory neurotransmitter γ-aminobutyric acid (GABA). Antibodies directed against GABA(A) receptor-associated protein, and the glycine-α1 receptor can also be observed. Paraneoplastic SPS is commonly associated with antiamphiphysin antibodies and breast cancer. Treatment of SPS with drugs that increase the GABAergic tone combined with immunotherapy can improve the neurological manifestations of these patients. The prognosis, however, is unpredictable and spontaneous remissions are unlikely.

---

### Stiff-person syndrome [^112XsFmw]. Practical Neurology (2025). Medium credibility.

Stiff-person syndrome (SPS) is an autoimmune disease associated mainly with antibodies to glutamic acid decarboxylase (GAD) or to glycine, characterised by intermittent painful spasms, stiffness and rigidity of the proximal and truncal muscles. Neuro-ophthalmological and gastrointestinal symptoms also occur. The symptoms are caused by neuronal excitability due to impaired inhibitory (gamma amino butyric acid [GABA] and glycine) neurotransmission. SPS is part of a larger spectrum of GAD antibody-spectrum disorders, which overlaps with autoimmune epilepsy, cerebellar ataxia, myoclonus, progressive encephalomyelitis, rigidity and myoclonus (PERM) and limbic encephalitis. PERM is often caused by antibodies against the glycine receptor. Some SPS cases are paraneoplastic. Diagnostic delay is often associated with irreversible disability, and therefore, clinicians need a high degree of clinical suspicion to make an earlier diagnosis. This review updates the various clinical presentations that should raise suspicion of SPS and its related conditions and includes a diagnostic algorithm and various treatment strategies including immunotherapy and GABA-ergic drugs.

---

### Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline [^114bpaLb]. Journal of Clinical Sleep Medicine (2025). High credibility.

American Academy of Sleep Medicine (AASM) guideline — no recommendation statements: The task force used 'no recommendation' when there was value in the findings but further research and innovation are needed because evidence was insufficient and inconclusive.

---

### Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults [^111fKmz7]. Journal of Clinical Sleep Medicine (2009). Medium credibility.

AASM levels of recommendation — definitions and certainty are categorized as follows: Standard is a generally accepted patient-care strategy that reflects a high degree of clinical certainty and generally implies the use of Level 1 Evidence or overwhelming Level 2 Evidence; Guideline reflects a moderate degree of clinical certainty and implies the use of Level 2 Evidence or a consensus of Level 3 Evidence; Option reflects uncertain clinical use and implies insufficient, inconclusive, or conflicting evidence or conflicting expert opinion.

---

### An unusual presentation of obstructive sleep apnoeas [^114yxTgj]. BMJ Case Reports (2009). Medium credibility.

We report the case of a 69-year-old married man who presented with features of irritability, characterised by outbursts of anger, short-term memory deficits and clumsiness, which progressed over a period of some 20 years. A detailed review elicited motor and verbal agitation during sleep, a history that was only available from his wife. He had excessive daytime sleepiness. A parasomnia in association with his possible neurological disorder was suspected and a referral made to the sleep disorders clinic. Further investigation with polysomnography determined that the abnormal behaviours during the night were secondary to arousals caused by obstructive sleep apnoea. Treatment with continuous positive airways pressure therapy prevented the abnormal behaviours at night, improved his daytime sleepiness but also led to improvements in his clumsiness, short-term memory and temper, all corroborated by his wife.

---

### 2017 ACC / AHA / HRS guideline for the evaluation and management of patients with syncope: a report of the American college of cardiology / American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society [^114t2V3j]. Circulation (2017). Medium credibility.

Psychogenic pseudosyncope — definition, features, and evaluation describes a syndrome of apparent loss of consciousness occurring in the absence of impaired cerebral perfusion or function that is an involuntary response and should not be confused with malingering or Munchausen syndrome. Patients are often young females with a higher prevalence of preexisting vasovagal syncope (VVS) or a history of physical and/or sexual abuse, with apparent duration of loss of consciousness often long (5 to 20 minutes) and episodes frequent, and common characteristics include closed eyes, lack of pallor and diaphoresis, and usually little physical harm. A normal pulse, blood pressure, or electroencephalogram (EEG) during a psychogenic pseudosyncope episode can be documented, and although many patients can be diagnosed with a careful history, tilt-table testing with or without transcranial Doppler and monitoring of an EEG is helpful.

---

### Minimal change nephrotic syndrome with stiff-person syndrome: is there a link? [^113oXmYs]. American Journal of Kidney Diseases (2005). Low credibility.

Stiff-person syndrome is a rare, likely immune-mediated neurological disorder characterized by painful spasms and progressive symmetric rigidity of the axial and proximal limb muscles. Rigidity of truncal muscles and continuous contraction of the agonist and antagonist muscles caused by involuntary motor-unit firing at rest are the hallmarks of stiff-person syndrome. Immunosuppressive therapy has induced remission in patients with stiff-person syndrome. We report a patient with stiff-person syndrome with minimal change nephrotic syndrome (MCNS). The pathophysiologic states of stiff-person syndrome and MCNS are unclear. T-Cell-dependent mechanisms are highly suspected for the pathogenesis of both. The diagnosis of stiff-person syndrome was made on the basis of clinical and laboratory findings, and both MCNS and stiff-person syndrome resolved completely with immunosuppressive therapy. To our knowledge, this is the first case of stiff-person syndrome in association with MCNS in the literature.

---

### Core diagnostic features of stiff person syndrome: insights from a case-control study [^116fP5wq]. Journal of Neurology (2025). Medium credibility.

Discussion

We present detailed sensitivity and specificity data from a large SPSD cohort, identifying key characteristics for diagnosis of both classic SPS and SPS-plus. Our study builds on previous research by clarifying which key clinical and paraclinical features enhance the diagnostic accuracy of SPSD and provide quantifiable data to distinguish SPSD from other neurologic conditions, which is a limitation in prior studies.

Our findings support prior observations of classic SPS presentation, with greater sensitivity for torso and lower extremity clinical presentation compared to upper extremity presentation (more common in amphiphysin antibody-associated disease). Hyperlordosis was the most specific physical exam finding, identifiable at the bedside and uncommon in SPSD mimickers. Given the diagnostic challenges and delays in care associated with misdiagnosis, recognizing this clinical feature could help facilitate proper work up, accurate diagnosis and treatment in the appropriate clinical contexts. Overall, this study provides additional support to the clinical picture of SPSD impacting the thoracolumbar musculature and highlights the importance of musculoskeletal exam findings.

---

### Clinical significance of sleepiness: an American Academy of Sleep Medicine position statement [^111DyMwa]. Journal of Clinical Sleep Medicine (2025). High credibility.

Abbreviation — OSA is defined, with OSA indicating obstructive sleep apnea.

---

### Treatment of central sleep apnea in adults: an American Academy of Sleep Medicine clinical practice guideline [^115Xv1uD]. Journal of Clinical Sleep Medicine (2025). High credibility.

Central sleep apnea management — good practice statement: Implementation is necessary for the appropriate and effective management of patients with CSA, the optimal approach should incorporate clinical features, co-morbid conditions, and polysomnographic findings in an individualized manner, clinicians must prioritize optimizing therapy for the conditions contributing to central apneas and improving patient-reported outcomes rather than solely focusing on eliminating disordered breathing events, and persistence of central respiratory events after therapy initiation should prompt re-evaluation of underlying risk factors and consideration of alternative treatment options.

---

### Expanding clinical profiles and prognostic markers in stiff person syndrome spectrum disorders [^113v2uhM]. Journal of Neurology (2024). Medium credibility.

Hypersensitivity triggers were reported in most patients with SPSD (though to a lesser degree than those who were partial SPS phenotype). These core clinical features are important to recognize in the diagnosis of SPSD especially since they can result in the most disabling and isolating aspects of a patient's disease (e.g. agoraphobia). Moreover, the presence of such features could help aide in an earlier diagnosis and be monitored for treatment over time. In fact, given how common these triggers are in SPSD, Dalakas and colleagues used a heightened sensitivity score as an outcome measure in SPS clinical trials which incorporates some of these common hypersensitivity triggers. Along the same lines, use of increased exteroceptive reflex on EMG may assist as well in diagnosis. In addition, there were other associated symptoms that have been less well recognized, but still frequently reported and identified, including gastrointestinal symptoms, cognitive dysfunction, mood disorders, and even photosensitivity. These less recognized symptoms are interesting and may suggest SPSD as a more multi-system disorder. It is important to identify these under-recognized symptoms of SPSD to allow for monitoring of disease and treatment of associated symptoms. There is some literature suggesting high incidence of and potentially an increased risk of psychiatric comorbidities in SPS. Recognizing the frequent confounding factors of psychiatric co-morbidities is important as to not mis-attribute such symptoms to psychiatric or psychogenic processes and also to improve the identification of these co-morbid conditions which need treatment.

---

### Management of refractory pain in stiff-person syndrome [^112LY9EZ]. BMJ Case Reports (2021). High credibility.

Stiff-Person syndrome (SPS) is a rare autoimmune neurological disorder characterised by episodic painful muscle rigidity and violent spasms. A significant trigger for the painful spasms experienced by patients is pain itself, making optimal pain management and avoidance a necessity. While first-line and second-line therapies for spasm prevention and termination are known, there is a paucity of evidence to guide pain management. We report the case of a 26-year-old woman with SPS referred for excruciating muscle cramping and rigidity with pain lasting beyond the episodes themselves. We report the novel use of ketamine and intravenous magnesium sulfate which may provide analgesia, spasm avoidance and early termination of exacerbations in SPS.

---

### Ictal apnea: a prospective monocentric study in patients with epilepsy [^1171g6P7]. European Journal of Neurology (2022). Medium credibility.

CONCLUSIONS

Our findings suggest that IA is a frequent ictal manifestation representative of a more extensive autonomic impairment in relation to focal seizures. Ictal respiratory changes and hypoxemia are often overlooked, because they are not reported by patients and are not revealed by an adequate respiratory polygraphic monitoring. We also recommend looking for ictal autonomic disruption in patients with epileptic encephalopathies to quantify the risk for SUDEP, already known to be higher in this population. In focal epilepsy, IA may represent a valuable ictal localizing sign toward the limbic network. Further investigations are needed to confirm these preliminary data and to determine whether IA recurrence might expose patients to higher risk of SUDEP.

---

### Obstructive and central sleep apnoea in a patient with medically intractable epilepsy [^116PJPGZ]. BMJ Case Reports (2022). High credibility.

A woman in her 30s with medically intractable epilepsy and Lennox-Gastaut Syndrome on multiple antiseizure medications and with a deep brain stimulator presented to the epilepsy monitoring unit with increased seizure frequency. She was noted to have periods of apparent apnoea time linked to bursts of epileptiform activity on continuous video EEG monitoring. Once the clinical seizures were controlled, she was discharged to the sleep laboratory. She was noted to have obstructive and central sleep apnoea, which improved with the use of positive airway pressure. Central sleep apnoeas were time linked to electrographic seizures. Ictal central apnoea can easily be overlooked and is likely more common than currently recognised in patients with epilepsy. Ictal central apnoea may be a biomarker for sudden unexpected death in epilepsy.

---

### Life-threatening perioperative anesthetic complications: major issues surrounding perioperative morbidity and mortality [^112nYfcD]. Trauma Surgery & Acute Care Open (2017). Low credibility.

Obstructive sleep apnea

Obstructive sleep apnea (OSA) is a modern diagnosis. In the study of Pickwickian persons, common threads arose leading to a formal syndrome. First appearing in the 1980s medical literature, it was often referred to as obesity hypoventilation syndrome. A New England Journal of Medicine report on sleep disordered breathing in middle-aged adults published in 1993 stirred the interest of a variety of physicians, including anesthesiologists. For anesthesiologists, the association of OSA with difficult airways was succinctly described in 1995 by Biro et al. Numerous studies followed regarding preoperative diagnosis using standardized questionnaires, the relative safety of allowing patients with OSA to undergo ambulatory surgery, predictive value of OSA in difficult intubationand what types of postoperative monitoring are most valuable.

OSA is described as the partial or complete obstruction of the upper airway with resulting arterial oxygen desaturation, increased carbon dioxide (CO₂) accumulation and importantly, excess sympathetic stimulation. Patients experience brief, repetitive cortical arousals that disrupt normal sleep with resultant excessive daytime sleepiness. Cohabiters of those with sleep apnea typically report habitual snoring in the patient with OSA as well as episodes of self-limited apnea. Therefore, additional questioning of significant others, roommates or family may be helpful (refer to figure 2).

---

### Diagnosis of obstructive sleep apnea in adults: a clinical practice guideline from theAmerican College of Physicians [^113C58wa]. Annals of Internal Medicine (2014). Medium credibility.

American College of Physicians (ACP) guideline — diagnosis of obstructive sleep apnea (OSA) in adults — recommendations are as follows: Recommendation 1: ACP recommends a sleep study for patients with unexplained daytime sleepiness. (Grade: weak recommendation; low-quality evidence) Recommendation 2: ACP recommends polysomnography for diagnostic testing in patients suspected of obstructive sleep apnea. ACP recommends portable sleep monitors in patients without serious comorbidities as an alternative to polysomnography when polysomnography is not available for diagnostic testing. (Grade: weak recommendation, moderate-quality evidence)

---

### Resolution of syncope with treatment of sleep apnea [^113mJzW5]. Journal of the American Board of Family Medicine (2008). Low credibility.

Sleep apnea is a common disorder associated with obesity and related health problems. Although treatment of sleep apnea may relieve some autonomic symptoms, it is currently unknown whether treatment of sleep apnea is specifically associated with the resolution of orthostatism and syncope. Herein we describe a 73-year-old man who had recurrent episodes of syncope. An extensive work-up, including cardiac and neurologic consultations, failed to identify the cause. An objective sleep evaluation led to the diagnosis of sleep apnea. Accordingly, the patient was treated with continuous positive airway pressure, which resolved the syncopal episodes. This case report generates a potentially important hypothesis that recurrent syncope may be effectively treated, in part, by correcting apnea. In patients with recurrent syncope of unknown etiology, a diagnosis of sleep apnea should be considered.

---

### Stiff-person syndrome and GAD antibody-spectrum disorders: GABAergic neuronal excitability, immunopathogenesis and update on antibody therapies [^111hFLic]. Neurotherapeutics (2022). Medium credibility.

Evolution of GAD-SD: a 65-Year Evolution after the Initial Description

The GAD-SD began with Stiff-Man Syndrome (SMS), described by Moersch and Woltman in 1956, characterized by muscle rigidity, hyperreflexia and spasms, mainly in the truncal and proximal leg muscles with excellent response to diazepam. The second hallmark observation was the description of autoantibodies against GAD by Solimena et al. who detected anti-GAD antibodies in both serum and cerebrospinal fluid, pointed out an immunological connection between SMS and DM1 and concluded that the clinical manifestations of SMS are related to disruption of GABAergic pathways, a notion still valid today. Subsequently, autoantibodies against synaptic proteins were described, first against amphiphysin in "three women with the stiff-man syndrome and breast cancer" and then against gephyrin in one SMS patient. On the clinico-neurophysiological side, understanding of SMS progressed with the description of abnormal excitotoxicity and paroxysmal autonomic dysfunction, recognition of clinical heterogeneity, and subdividing SMS into stiff trunk (man) syndrome, stiff limb syndrome and progressive encephalomyelitis with rigidity.

It was in 1999–2000 when in the largest at that time series of examined patients, the clinical spectrum and diagnostic criteria valid today were described, while the term Stiff-Person Syndrome (SPS) was introduced based on the observations that more patients were women, hence the more appropriate term "person"-rather than "man", especially since in previous publications it was referred even in the title as "three women with stiff-man syndrome". Over the ensuing years, the pathomechanism of SPS was further characterized with novel electrodiagnostic neuronal excitability studies; GABA measurements in the CSF and brain with MRS spectroscopy; immunological studies including GAD epitopes and search for other antibodies affecting GABAergic neurotransmission; performance of two controlled clinical trials; and defining the natural history of the disease based on the largest series of SPS patients examined by the same clinicians longitudinally over a 20 year period.

---

### Core diagnostic features of stiff person syndrome: insights from a case-control study [^111tUxxe]. Journal of Neurology (2025). Medium credibility.

Clinical presentation

In classic SPS, torso and lower extremity symptoms were sensitive (89.1%; 98.1%, respectively) but lacked specificity (50.0%, 13.1%, respectively). Each of these variables were associated with a diagnosis of classic SPS (OR 7.9, 95% CI 3.6–17.6; OR 7.4, 95% CI 1.9–29.1, respectively). For SPS-plus, brainstem and cerebellar symptoms were highly specific (100%, 98.5%, respectively) but not sensitive (26.7%, 24.4%, respectively). Odds ratio was not calculated for brainstem symptoms due to 100% specificity, but it was for cerebellar symptoms and these symptoms were also associated with an SPS-plus diagnosis (OR 21.0, 95% CI 2.6–170). Upper extremity symptoms were not associated with a diagnosis of either phenotype.

Hypersensitivity triggers associated with a classic SPS diagnosis included unexpected noise (OR 13.9, 95% CI 5.9–32.7), fear of open space (OR 11.8, 95% CI 4.7–29.9), exposure to cold (OR 6.8, 95% CI 3.2–14.7), stress (OR 27.0, 95% CI 8.4–86.8), and agoraphobia (OR 16.2, 95% CI 6.1–43.3). The same triggers were associated with a diagnosis of SPS-plus (Table 2). The only trigger that was highly specific was agoraphobia (86.7%), and stress as a symptom trigger was the most sensitive (96.8%). Both were associated with a diagnosis of classic SPS (OR 7.9, 95% CI 3.6–17.6; OR 7.4, 95% CI 1.9–29.1, respectively).

---

### Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline [^114MMK7v]. Journal of Clinical Sleep Medicine (2017). Medium credibility.

American Academy of Sleep Medicine guideline — recommendation strength is defined such that "A STRONG recommendation is one that clinicians should, under most circumstances, always follow (i.e., something that might qualify as a Quality Measure)", while "A WEAK recommendation reflects a lower degree of certainty in the appropriateness of the patient-care strategy and requires that the clinician use his/her clinical knowledge and experience, and refer to the individual patient's values and preferences to determine the best course of action".

---

### Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline [^116tttP7]. Journal of Clinical Sleep Medicine (2017). Medium credibility.

Obstructive sleep apnea (OSA) good practice statements — "Diagnostic testing for OSA should be performed in conjunction with a comprehensive sleep evaluation and adequate follow-up", and the clinical evaluation "should include a thorough sleep history and a physical examination that includes the respiratory, cardiovascular, and neurological systems", with particular attention to "snoring, witnessed apneas, nocturnal choking or gasping, restlessness, and excessive sleepiness"; follow-up "under the supervision of a board-certified sleep medicine physician" ensures appropriate communication of findings and access to expertise.

---

### Management of obstructive sleep apnea in adults: a clinical practice guideline from the American College of Physicians [^1132GdHv]. Annals of Internal Medicine (2013). Medium credibility.

Obstructive sleep apnea — continuous positive airway pressure (CPAP) with or without humidification has strength of evidence rated as "Insufficient".

---

### Practice guidelines for the perioperative management of patients with obstructive sleep apnea: an updated report by the American society of anesthesiologists task force on perioperative management of patients with obstructive sleep apnea [^111uMrKD]. Anesthesiology (2014). Medium credibility.

Regarding classification and risk stratification for obstructive sleep apnea, more specifically with respect to risk factors, ASA 2014 guidelines recommend to recognize that the following patient characteristics may be associated with obstructive apnea:

- abnormal cephalometric measurements

- hypertension

- diabetes mellitus

- stroke

- myocardial infarction.

---

### Therapies in stiff-person syndrome: advances and future prospects based on disease pathophysiology [^113T3q3Q]. Neurology (2023). Medium credibility.

Among the glutamic acid decarboxylase (GAD)-antibody–spectrum disorders, the most common phenotypic subset is the stiff-person syndrome (SPS), caused by impaired GABAergic inhibitory neurotransmission and autoimmunity characterized by very high titers of GAD antibodies and increased GAD-IgG intrathecal synthesis. If not properly treated or untreated because of delayed diagnosis, SPS progresses leading to disability; it is therefore fundamental to apply the best therapeutic schemes from the outset. This article is focused on the rationale of specific therapeutic strategies based on the SPS pathophysiology targeting both the impaired reciprocal GABAergic inhibition to symptomatically improve the main clinical manifestations of stiffness in the truncal and proximal limb muscles, gait dysfunction, and episodic painful muscle spasms and the autoimmunity to enhance improvement and slow down disease progression. A practical, step-by-step therapeutic approach is provided, highlighting the importance of combination therapies with the preferred gamma-aminobutyric acid–enhancing antispasmodic drugs, such as baclofen, tizanidine, benzodiazepines, and gabapentin, that provide the first-line symptomatic therapy, while detailing the application of current immunotherapies with intravenous immunoglobulin (IVIg) plasmapheresis, and rituximab. The pitfalls and concerns of long-term therapies in different age groups, including children, women planning pregnancy, and especially the elderly considering their comorbidities are emphasized, also highlighting the challenges in distinguishing the conditioning effects or expectations of chronically applied therapies from objective meaningful clinical benefits. Finally, the need for future targeted immunotherapeutic options based on disease immunopathogenesis and the biologic basis of autoimmune hyperexcitability are discussed, pointing out the unique challenges in the design of future controlled clinical trials especially in quantifying the extend and severity of stiffness, episodic or startle-triggered muscle spasms, task-specific phobias, and excitability.

---

### Clinically disparate stiff-person syndrome with GAD65 autoantibody in a father and daughter [^111JnYAk]. Neurology (2003). Low credibility.

Stiff-person syndrome (SPS) is a sporadic autoimmune disorder characterized by muscle stiffness with painful spasms and usually a high level of GAD65 antibody. The authors report familial SPS associated with GAD65 antibody. The clinical presentations were disparate; the father had an appendicular form of SPS and the daughter's axial SPS presented with episodic opisthotonos.

---

### Stiff person syndrome and pregnancy [^114CspGY]. Obstetrics and Gynecology (2011). Low credibility.

Background

Stiff person syndrome, also known as Moersche-Woltman syndrome, is a debilitating disorder that is rarely seen in the pregnant patient. It is characterized by muscle spasms triggered by startle, voluntary movement, or tactile or emotional stimuli, occurring predominantly in the axial musculature.

Case

A woman diagnosed with stiff person syndrome became pregnant 2 months after her diagnosis. Her medication regimen was adjusted because of pregnancy, and anesthesia was initiated early in labor to control her pain. She was able to have a full-term pregnancy with few complications.

Conclusion

Stiff person syndrome may be successfully managed in pregnancy. Patients can deliver vaginally with adequate pain control to avoid muscle spasms.

---

### A practical guide to the therapy of narcolepsy and hypersomnia syndromes [^112LV7Hx]. Neurotherapeutics (2012). Low credibility.

To address this issue, we generally have a conservative common sense attitude so that patients with a high risk of sleep apnea or hypoventilation are monitored with polysmnography and CO₂ monitoring while taking the drug. If there is significant disease, they are then treated with positive airway pressure (PAP) therapy first prior to the introduction of sodium oxybate, which paradoxically helps tolerate the PAP therapy in narcoleptic patients who can often have disturbed nocturnal sleep masked by sleep apnea. Not uncommonly, we conduct titration of PAP under the influence of sodium oxybate, or restudy patients using polysomnography once a stable dose has been established. This is also systematically done if the response to sodium oxybate therapy on narcolepsy symptoms has not been as good as anticipated.

Second, clinical trials have shown that administration of sodium oxybate slightly increases anxiety ratings in many trials, although not always significantly, or in the pathological range. Other investigators have noted that in some rare cases reported as case reports, psychiatric complications may emerge, ranging from increased anxiety, to depression or even psychosis. Although not established, it is our experience that these effects are likely the result of increased daytime anxiety on a premorbid personality. For example, increased anxiety, depression, or a paradoxical feeling that the drug makes the sleepiness even worse can be the result of increased anxiety in a subject already pathologically anxious at baseline. Similarly, an individual with a paranoid personality may be biased toward having persecution delusions (similar to when stimulants are added). These effects are typically reversible once sodium oxybate is stopped, although it is not uncommon for us to then first add a course of SSRI to reduce anxiety and then reintroduce sodium oxybate with good results. Although these side effects are rare, this is an area in need of more research, as proper psychiatric screening is likely helpful to avoid potential problems if there is suspicion of psychiatric comorbidity. The situation is often complex in children and subjects close to onset, as in our experience a number of patients may develop narcolepsy together with behavioral disturbances secondary to sleepiness or a bona fide psychiatric disorder, such as schizophrenia, possibly the result of a larger autoimmune process.

---

### Core diagnostic features of stiff person syndrome: insights from a case-control study [^116LEUTx]. Journal of Neurology (2025). Medium credibility.

Introduction

Stiff person syndrome spectrum disorders (SPSD) are a rare group of autoimmune neurologic disorders that most often affect the truncal and limb musculature with progressive muscle rigidity and painful spasms. Classic stiff person syndrome (SPS) has been associated with glutamic acid decarboxylase-65 (GAD65) antibodies, though these have also been associated with a wide variety of other clinical phenotypes, including SPS-plus (classic features of SPS with additional cerebellar and/or brainstem dysfunction), cerebellar ataxia (CA), stiff-limb syndrome (SPS symptoms isolated to one limb or trunk), progressive encephalomyelitis with rigidity and myoclonus (PERM), refractory epilepsy, and autoimmune encephalitis. There may be overlap between presentations, suggesting a spectrum of disease.

Besides GAD65 antibodies, amphiphysin and glycine receptor antibodies are seen in association with SPSD. In addition, SPSD patients may develop other symptoms that impact them differentially (e.g. agoraphobia). Diagnosis of these conditions can be challenging, even with proposed diagnostic criteria. While these criteria share common features, including episodic spasms, axial stiffness, positive GAD65 antibodies, characteristic electrophysiologic findings, and exclusion of alternative etiologies, it remains unclear which of these features hold the greatest diagnostic value. Moreover, the lack of awareness for these diseases and absence of consensus diagnostic criteria leads to a diagnosis latency of several years, or misdiagnosis/overdiagnosis. This is particularly challenging in non-classical phenotypes due to their rarity. To aid accurate and timely diagnoses, we aimed to identify clinical and paraclinical features most predictive of SPSD by comparing confirmed cases with those who were evaluated for suspected SPSD but were ultimately found to have an alternative diagnosis. Additionally, we identified common misdiagnoses and SPSD features associated with misdiagnosis.

---

### Core diagnostic features of stiff person syndrome: insights from a case-control study [^117HaNcM]. Journal of Neurology (2025). Medium credibility.

Examination findings

In classic SPS, hyperlordosis was the most specific exam finding (87.1%) but not highly sensitive (62.6%), though it was still associated with diagnosis (OR 11.9, 95% CI 5.1–27.3). Gait abnormalities and rigidity/stiffness were highly sensitive (91.4%, 88.2%, respectively) but less specific (35.9%, 68.8%, respectively). Each was associated with a classic SPS diagnosis. In SPS-plus, ocular motor dysfunction was both sensitive and specific (80.0%, 81.6% respectively) and highly associated with diagnosis (OR 17.7, 95% CI 5.7–55). Dysarthria was also highly specific (86.5%, OR 21.3, 95% CI 6.4–71). Similar to classic SPS, hyperlordosis was highly specific (87.1%, OR 14.1, 95% CI 5.1–38.7) for SPS-plus but not a sensitive exam finding (67.6%).

Univariate analysis revealed that hyperlordosis, abnormal gait, hyperreflexia, rigidity/stiffness, paravertebral muscle abnormalities, and abdominal spasms were all associated with a diagnosis of both classic SPS and SPS-plus. Ataxia, ocular motor dysfunction, and dysarthria were associated with a diagnosis of SPS-plus.

---

### Brief resolved unexplained events (formerly apparent life-threatening events) and evaluation of lower-risk infants [^11748BDs]. Pediatrics (2016). Medium credibility.

Recommendation strength interpretation — language cues and definitions: Strong and moderate recommendations are associated with "should" and "should not" statements, whereas a weak recommendation may be recognized by "may" or "need not". A strong recommendation means the benefits of the recommended approach clearly exceed the harms (or, for a strong negative recommendation, the harms clearly exceed the benefits) and the supporting evidence quality is excellent; clinicians are advised to follow such guidance unless a clear and compelling rationale for acting in a contrary manner is present. A moderate recommendation means the committee believes benefits exceed harms (or harms exceed benefits for a negative recommendation) but the evidence on which the recommendation is based is not as strong, and clinicians are encouraged to follow such guidance while remaining alert to new information and sensitive to patient preferences. A weak recommendation means the existing evidence quality is suspect or well-designed, well-conducted studies have shown little clear advantage to one approach versus another, offering clinicians flexibility in decision-making, although boundaries on alternatives may be set.

---

### Treatment of central sleep apnea in adults: an American Academy of Sleep Medicine clinical practice guideline [^116NUbRY]. Journal of Clinical Sleep Medicine (2025). High credibility.

Regarding respiratory support for central sleep apnea, more specifically with respect to positive airway pressure therapy, AASM 2025 guidelines recommend to consider offering bilevel positive airway pressure with a backup rate in patients with CSA due to primary CSA, CSA due to medication or substance use, treatment-emergent CSA, and CSA due to a medical condition or disorder.

---

### Prolonged disorder of consciousness: giving a second opinion on the best interests of a person [^115JodtW]. Practical Neurology (2025). Medium credibility.

Patients with a prolonged disorder of consciousness have a neurological disorder. Few neurologists undertake assessment and management after the acute phase of the person's illness, even though some of their patients with progressive neurological disorders become persistently unconscious. Their clinical evaluation and deciding on their best interests require full use of a neurologist's expertise, which is intellectually, emotionally and clinically challenging. I will cover essential aspects of giving such an expert second opinion based on at least 200 cases where I have done so (and over 500 patients seen clinically).

---

### Therapies in stiff-person syndrome: advances and future prospects based on disease pathophysiology [^114uwzvg]. Neurology (2023). Medium credibility.

Intravenous Immunoglobulin

In a double-blind, placebo-controlled trial we conducted more than 20 years ago in GAD-positive patients with SPS, IVIg showed significant improvements in objective stiffness parameters based on validated quantitative scales, hyperexcitability scores, and activities of daily living. Patients experienced reduced stiffness, especially in the paraspinal muscles with more muscle flexibility; less falls; improvement in their gait becoming able to walk without assisted devices (Figure 4, A and B); and with substantial reduction of anxiety-triggered spasms becoming able to perform again most of daily activity functions. In that trial, based on predefined criteria, the stiffness scores significantly decreased and the heightened-sensitivity scores were markedly reduced after 3 monthly IVIG infusions; the symptoms started, however, to rebound 4–6 weeks after the patients switched to placebo. This pivotal study has conclusively shown that after 3 monthly infusions, IVIg was effective in up to 75% of patients with SPS who were symptomatic with inadequate response to antispasmodic and GABA-enhancing drugs.

Figure 4
Response to IVIg or Rituximab in 2 Representative Patients Who Participated in the Double-Blind Placebo Control Trials With IVIg (A and B) or Rituximab (C and D)

(A, B) Before therapy, this patient who participated in the controlled studywas very stiff, unable to bend down or walk unassisted requiring a walker (A). After 3 monthly infusions of IVIg, she had an impressive improvement, not requiring any more assistive devices, being able to bend down and walk independently (B). (C, D) Before rituximab, this patient who participated in the large controlled studywas very stiff and unable to walk independently requiring 2 walking canes (C). He was randomized to rituximab and started to improve after 3 months; by the 6th month after the infusion, he had become independent in his walking abilities to the point of even went skiing (D). His improvement lasted several months thereafter.

---

### Therapies in stiff-person syndrome: advances and future prospects based on disease pathophysiology [^117AUqyv]. Neurology (2023). Medium credibility.

Among the glutamic acid decarboxylase (GAD)-antibody-spectrum disorders, the most common phenotypic subset is the stiff-person syndrome (SPS), caused by impaired GABAergic inhibitory neurotransmission and autoimmunity characterized by very high titers of GAD antibodies and increased GAD-IgG intrathecal synthesis. If not properly treated or untreated because of delayed diagnosis, SPS progresses leading to disability; it is therefore fundamental to apply the best therapeutic schemes from the outset. This article is focused on the rationale of specific therapeutic strategies based on the SPS pathophysiology targeting both the impaired reciprocal GABAergic inhibition to symptomatically improve the main clinical manifestations of stiffness in the truncal and proximal limb muscles, gait dysfunction, and episodic painful muscle spasms and the autoimmunity to enhance improvement and slow down disease progression. A practical, step-by-step therapeutic approach is provided, highlighting the importance of combination therapies with the preferred gamma-aminobutyric acid-enhancing antispasmodic drugs, such as baclofen, tizanidine, benzodiazepines, and gabapentin, that provide the first-line symptomatic therapy, while detailing the application of current immunotherapies with intravenous immunoglobulin (IVIg) plasmapheresis, and rituximab. The pitfalls and concerns of long-term therapies in different age groups, including children, women planning pregnancy, and especially the elderly considering their comorbidities are emphasized, also highlighting the challenges in distinguishing the conditioning effects or expectations of chronically applied therapies from objective meaningful clinical benefits. Finally, the need for future targeted immunotherapeutic options based on disease immunopathogenesis and the biologic basis of autoimmune hyperexcitability are discussed, pointing out the unique challenges in the design of future controlled clinical trials especially in quantifying the extend and severity of stiffness, episodic or startle-triggered muscle spasms, task-specific phobias, and excitability.

---

### Impact of obstructive sleep apnea syndrome on endothelial function, arterial stiffening, and serum inflammatory markers: an updated meta-analysis and metaregression of 18 studies [^113A1oCA]. Journal of the American Heart Association (2015). Low credibility.

OSAS Definition, Study End Points, and Measurements

The apnea‐hypopnea index (AHI) was defined as the average number of episodes of apneas and hypopneas per hour of sleep. OSAS was defined in events per hour as AHI ≥ 5. Participants were categorized into the following 4 subgroups according to their AHI values: healthy persons (AHI < 5) and patients with OSAS that was mild (AHI 5 to < 15), moderate (AHI 15 to < 30), or severe (AHI ≥ 30). Moderate–severe OSAS was defined as AHI ≥ 15; mild–moderate OSAS was defined as AHI 5 to < 30. The primary end point was the difference in serum levels of CRP and TNF‐α, arterial stiffness, and vascular endothelial function between patients with OSAS and controls. The control group included persons without OSAS.

Endothelial function was evaluated by brachial artery dilatation in response to hyperemia (represented by flow‐mediated dilation [FMD]) or nitroglycerin (NTG; represented by NTG‐induced dilation), which was calculated as the percentage change in arterial diameter on stimulation relative to resting values. Arterial stiffness was determined by carotid‐femoral pulse wave velocity (PWV), which reflects the amount of time that the pulse wave generated by the contracting heart needs to travel to the periphery and to be reflected back. 2, 27 Augmentation index (AIx) was also determined to estimate arterial stiffness. The inflammatory response in patients was evaluated by serum levels of hsCRP/CRP and TNF‐α. The definition and units of the indices of endothelial function, arterial stiffness, and inflammatory markers are displayed in Table 1.

Table 1
Definition and Units of the Indices of Endothelial Function, Arterial Stiffness, and Inflammatory Markers

Data Extraction and Quality Assessment

Two reviewers (J.W and W.Y.) extracted the following information from the eligible studies independently: first author's surname, year of publication, country of origin, study design, sample size of OSAS and control groups, means and standard deviations of FMD, NTG‐induced dilation, carotid‐femoral PWV, AIx, and serum levels of hsCRP/CRP and TNF‐α in both groups. If studies contained multiple categories of OSAS or body mass index (BMI), data were extracted at each category as independent studies. The 11 items recommended by the US Agency for Healthcare Research and Quality (AHRQ) for assessing the quality of cross‐sectional studies were used to assess the quality of the included studies. 28

---

### Perioperative treatment of patients with obstructive sleep apnea [^114RLWuF]. Current Opinion in Pulmonary Medicine (2004). Low credibility.

Purpose Of Review

Obstructive sleep apnea is a common disorder. Despite reports of its role as a risk factor for postoperative morbidity and mortality, only a few investigators have examined the optimal treatment of patients during this vulnerable period. Recognition of obstructive sleep apnea during conscious sedation or in the perioperative period is important to prevent the occurrence of adverse outcomes. This review discusses the influence of sedative, anesthetic, and analgesic agents and other factors during the perioperative period on patients with obstructive sleep apnea. The aim of this article is to emphasize the importance of recognizing and appropriately treating surgical patients with obstructive sleep apnea.

Recent Findings

Sedative, analgesic, and anesthetic agents used perioperatively play a major role in the development of sleep-disordered breathing during the postoperative period. Postoperative apneic episodes frequently occur even after surgery remote from the upper airway. Sleep apnea predisposes patients to a greater than normal risk for postsurgical complications. Adequate screening of patients preoperatively and initiation of continuous positive airway pressure therapy perioperatively could prevent serious complications, including hypoxemia, arrhythmias, myocardial infarction, and respiratory arrest.

Summary

Obstructive sleep apnea places a significant proportion of surgical patients at increased risk of perioperative complications. Obstructive sleep apnea can be induced, unmasked, or exacerbated by the effects of sedative, analgesic, and anesthetic agents regardless of the site of surgery. The role of sleep apnea as a risk factor for development of postoperative complications needs greater emphasis. Increased awareness of the risk posed by an obstructed upper airway and appropriate management are important to optimize the perioperative care of patients with obstructive sleep apnea.

---

### Stiff man syndrome and related conditions [^115FLyXb]. Movement Disorders (2002). Low credibility.

The stiff man syndrome (SMS) and its variants, focal SMS, stiff limb (or leg) syndrome (SLS), jerking SMS, and progressive encephalomyelitis with rigidity and myoclonus (PERM), appear to occur more frequently than hitherto thought. A characteristic ensemble of symptoms and signs allows a tentative clinical diagnosis. Supportive ancillary findings include (1) the demonstration of continuous muscle activity in trunk and proximal limb muscles despite attempted relaxation, (2) enhanced exteroceptive reflexes, and (3) antibodies to glutamic acid decarboxylase (GAD) in both serum and spinal fluid. Antibodies to GAD are not diagnostic or specific for SMS and the role of these autoantibodies in the pathogenesis of SMS/SLS/PERM is the subject of debate and difficult to reconcile on the basis of our present knowledge. Nevertheless, evidence is emerging to suggest that SMS/SLS/PERM are manifestations of an immune-mediated chronic encephalomyelitis and immunomodulation is an effective therapeutic approach.

---

### Evaluation and management of obesity hypoventilation syndrome. An official American Thoracic Society clinical practice guideline [^111qoMk7]. American Journal of Respiratory and Critical Care Medicine (2019). High credibility.

Regarding specific circumstances for obesity, more specifically with respect to patients with hypoventilation syndrome (respiratory support), ATS 2019 guidelines recommend to consider initiating CPAP therapy rather than noninvasive ventilation as first-line therapy in stable ambulatory patients with obesity hypoventilation syndrome and concomitant severe obstructive sleep apnea (apnea-hypopnea index ≥ 30 events/hour).

---

### Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline [^116BGnpK]. Journal of Clinical Sleep Medicine (2025). High credibility.

American Academy of Sleep Medicine guideline — implications of strong versus conditional recommendations are defined for clinicians, patients, and policy makers. For strong recommendations, clinicians are told that almost all patients should be offered the recommended course of action and that adherence could be used as a quality criterion or performance indicator; patients are told almost all patients should be offered the recommended course of action, although a small proportion would not choose it; and policy makers are told the recommended course of action can be adopted as policy for most situations and adherence could be used as a quality criterion or performance indicator. For conditional recommendations, clinicians are told most patients should be offered the suggested course of action, but different choices may be appropriate and clinicians must help determine if the suggestion is clinically appropriate and consistent with values and preferences; patients are told most patients should be offered the suggested course of action, although some may not choose it, and they should work with their clinician to determine if it is clinically appropriate and consistent with their values and preferences; and policy makers are told the ultimate judgment must be made by the clinician and patient together based on what is best for the patient, and this flexibility should be accounted for when establishing policies.

---

### Management of persistent, post-adenotonsillectomy obstructive sleep apnea in children: an official American Thoracic Society clinical practice guideline [^112UUxzC]. American Journal of Respiratory and Critical Care Medicine (2024). High credibility.

Regarding specific circumstances for obstructive sleep apnea, more specifically with respect to pediatric patients (persistent symptoms), ATS 2024 guidelines recommend to consider offering CPAP treatment in pediatric patients with persistent OSA not qualifying for site-specific upper airway treatment.

---

### SPS: understanding the complexity [^11571Xkh]. Journal of the Neurological Sciences (2019). Medium credibility.

Introduction

Stiff-person syndrome (SPS), first described in 1956 by Moersch and Woltman, is a progressive autoimmune disorder with core features of chronic fluctuating progressive truncal and limb rigidity and painful muscle spasms leading to gait difficulties, falls and an appearance that resembles tin soldiers. The syndrome is a rare, highly disabling disorder of the central nervous and frequently results in significant disability. Understanding of the etiology, clinical spectrum, diagnostic workup and therapeutic modalities for this painful and disabling disorder has vastly evolved over the past few years with more confidence in classifying and treating the patients. The purpose of this review is to increase the awareness, early detection, and treatment of this disabling disease.

Method

PubMed was searched, all date inclusive, using the following phrases: stiff person syndrome, anti-Glutamic acid decarboxylase (Anti-GAD) antibody syndrome, Progressive encephalomyelitis with rigidity and myoclonus (PERM), and Paraneoplastic Stiff Person syndrome. No filters or restrictions were used. A total of 888 articles were identified.

Results

The results were narrowed to 190 citations after excluding non-English and duplicate reports. Clinical presentation, laboratory testing, treatment, and prognosis were categorized and summarized.

Discussion

In this article we will discuss the epidemiology, presentation and classification. Explain the pathophysiology of SPS and the autoimmune mechanisms involved. Discuss the diagnostic approach and treatments available, as well as, the prognosis and outcome.

---

### Prevalence, clinical profiles, and prognosis of stiff-person syndrome in a Japanese nationwide survey [^113XvgjE]. Neurology (2023). Medium credibility.

Introduction

Stiff-person syndrome (SPS) is a rare autoimmune neurologic disorder characterized by progressive axial muscle stiffness, CNS hyperexcitability, and stimulus-sensitive painful muscle spasms. Women are predominantly affected (62–70% of cases), with most patients presenting in their 40s to 50s.SPS is classified into classic SPS and SPS variants, including stiff-limb syndrome (SLS) and progressive encephalomyelitis with rigidity and myoclonus (PERM), on the basis of clinical presentation. Most patients with SPS have antibodies against glutamic acid decarboxylase 65 (GAD65), the rate-limiting enzyme in the production of the inhibitory neurotransmitter γ-aminobutyric acid (GABA). Amphiphysin antibodies are also detected in some patients with paraneoplastic SPS. Patients with PERM may present with symptoms similar to classic SPS but with additional features, including brainstem symptoms, hyperekplexia, myoclonus, and dysautonomia. PERM is associated with glycine receptor (GlyR) α1 subunit antibodies and generally responsive to immunotherapy. Since the initial description of SPS in 1956, marked progress has been made in the clinical characterization of SPS. However, no large-scale epidemiologic studies have been conducted except for 1 clinic-based study that reported an estimated prevalence of one to two cases per million population.GAD65 antibodies are useful diagnostic markers, but their role in the pathogenesis of SPS is unclear. Moreover, their clinical relevance is questionable in patients with low GAD65 antibody titers. It has also been reported that the outcome is poor in patients with GAD65 antibodies. As some patients respond poorly to conventional immunotherapies, the exact nature of GAD65 antibody-associated SPS needs to be clarified. Against this backdrop, we conducted a nationwide epidemiologic survey of SPS in Japan and compared the clinical features among different immunologic groups (autoantibody-associated patients).

---

### Antiglycine receptor-related stiff limb syndrome in a patient with chronic lymphocytic leukaemia [^113HogfC]. BMJ Case Reports (2013). Medium credibility.

We report a 61-year-old man presenting with rapidly progressive stiffness and painful muscle spasms in the lower extremity muscles. The patient was diagnosed with chronic lymphocytic leukaemia (CLL) approximately a year before symptom onset. Electromyography displayed continuous motor unit activity and immunocytochemistry showed a positive staining for antiglycine receptor (anti-GlyR) antibodies. The clinical course was complicated by autonomic instability and cardiac arrest, but stabilised under continuous therapy with plasma exchange and symptomatic treatment with baclofen and clonazepam. Anti-GlyR antibodies induce rare, but severe, variants of stiff person syndrome that can be of paraneoplastic origin and life threatening due to autonomic dysfunction.

---

### Severe stiff-person syndrome after COVID: the first video-documented COVID exacerbation and viral implications [^1126Jc3Y]. Neurology (2024). Medium credibility.

Introduction

Stiff-person syndrome (SPS) is characterized by stiffness in the limb and axial muscles, episodic painful muscle spasms often triggered by anxiety and task-specific phobias, and startle responses resulting in stiff and spastic gait and uncontrolled falls steadily leading to disability.SPS is due to autoimmune neuronal hyperexcitability connected to impaired reciprocal GABAergic inhibition associated with very high GAD-65 antibody titers in the serum and CSF. Except in cases of paraneoplastic association, it is unknown what triggers SPS, especially the sudden onset of long-lasting spasms. Although viruses have been implicated as triggers in various autoimmune diseases, there is no evidence that they have a role in SPS either as disease triggers or as inducers of severe postviral exacerbation, except of 1 case associated with West Nile Virus (WNV) infection. Although up to 35% of patients with SPS have GAD-positive diabetes mellitus type 1 (DM1), and some cases with DM1 are reportedly triggered or worsened by enteroviruses and COVID-19, there is no evidence that these viruses can also acutely trigger or worsen SPS. This is especially relevant because COVID-19 has been implicated in triggering several neuronal autoimmunities.

We now describe the first case of a patient with very mild GAD-positive stiff-leg syndrome (SLS) with disease limited to the left leg who was fully functioning for years, but 1 week after COVID-19 started to worsen and over 3 weeks developed severe full-blown SPS becoming acutely disabled due to generalized — video-documented — severe stiffness and spasms. Because his newly developed SPS has been steadily improving with IVIg, the case suggests an enhanced viral-triggered GAD antibody–associated autoimmunity.

---

### Evaluation and management of obesity hypoventilation syndrome. An official American Thoracic Society clinical practice guideline [^112yUDMU]. American Journal of Respiratory and Critical Care Medicine (2019). High credibility.

Regarding specific circumstances for obesity, more specifically with respect to patients with hypoventilation syndrome (respiratory support), ATS 2019 guidelines recommend to consider initiating positive airway pressure therapy during sleep in stable ambulatory patients with obesity hypoventilation syndrome.

---

### Stiff-person syndrome treated with rituximab [^116kaLmf]. BMJ Case Reports (2010). Medium credibility.

Stiff-person syndrome (SPS) is a rare neurological condition consisting of progressive and fluctuating rigidity of the axial muscles combined with painful spasms. The pathophysiology of SPS is not fully understood, but there seems to be an autoimmune component. The use of rituximab, a chimeric monoclonal antibody targeting CD20 protein in the surface of mature B cells, for the treatment of SPS is a recent therapeutical approach showing promising results. The authors present a case report of a 41-year-old female patient diagnosed with SPS who was treated with rituximab in a public hospital in Brasília, Brazil, showing a good and safe response to the treatment so far. Our data go along with some recent articles published in the literature.

---

### Stiff person syndrome and type 1 diabetes mellitus: a case of the chicken or the egg? [^116aYSqk]. Journal of General Internal Medicine (2019). Medium credibility.

Anti-glutamic acid decarboxylase (anti-GAD) antibodies are linked with both autoimmune diabetes and the rare neurological disorder stiff person syndrome (SPS). SPS is an uncommon autoimmune-mediated condition characterized by painful episodic spasms and progressive muscle rigidity. We present the case of a 23-year-old non-diabetic, insulin-naïve woman with known SPS who was hospitalized for SPS-related symptomatology. The patient quickly developed type 1 diabetes mellitus (T1DM) with unexpectedly large insulin requirements. To our knowledge, there are no other reports describing rapid T1DM development during an acute hospitalization for SPS and fewer than 5 case reports describing the association of SPS with extreme insulin resistance. Our case highlights the key clinical features, pathology, and pathogenesis of both SPS and T1DM and explores the relationship between the two disease processes.

---

### Paraneoplastic "stiff person syndrome" with metastatic adenocarcinoma and anti-Ri antibodies [^113GjcBN]. Neurology (2004). Low credibility.

A 43-year-old woman presented with clinical and electrophysiologic features of stiff person syndrome (SPS), without abdominal or lumbar paraspinal muscle involvement. Investigations revealed metastatic adenocarcinoma of the lung with positive anti-Ri antibodies. Her clinical condition improved with diazepam, baclofen, tizanidine, and palliative chemotherapy. Screening for an underlying malignancy and anti-Ri antibodies should be considered in patients with SPS when clinical presentation is atypical.

---

### 2024 guideline for the primary prevention of stroke: a guideline from the American Heart Association / American stroke association [^112eMoXz]. Stroke (2024). High credibility.

Regarding specific circumstances for acute ischemic stroke, more specifically with respect to patients with obstructive sleep apnea, AHA/ASA 2024 guidelines recommend to consider offering CPAP in patients with obstructive sleep apnea to reduce the risk of stroke.

---

### An official multi-society statement: the role of clinical research results in the practice of critical care medicine [^112qqd8f]. American Journal of Respiratory and Critical Care Medicine (2012). Medium credibility.

Critical care medicine — incorporation of clinical research results in practice is framed within a debate about the relative value of research for guiding clinical decision making alongside other forms of medical knowledge, and professional organizations offer a conceptual framework rather than a statement for or against evidence-based medicine. No single form of medical knowledge always takes precedence, and no hierarchy of knowledge can be uniformly applied to clinical decisions. The aim is not to resolve current controversies but to provide clinicians with a conceptual background and framework for evaluating discordant information and conflicting claims when caring for the critically ill. Bedside care of critically ill patients requires real-time analysis and rapid decisions, and the vulnerability of these patients, their general inability to participate directly in medical decision making, and the high risk of poor outcome amplify the clinician's responsibility. Use of clinical research in critical care is complicated by complex syndromic classifications, lack of reliable syndrome definitions, heterogeneity and co-morbidities, and a relative paucity of large, randomized trials to inform practice.

---

### Fentanyl (abstral) [^111aFW6L]. FDA (2012). Low credibility.

10 OVERDOSAGE

10.1 Clinical Presentation

The manifestations of ABSTRAL overdosage are expected to be similar in nature to intravenous fentanyl and other opioids, and are an extension of its pharmacological actions with the most serious significant effect being hypoventilation [see Clinical Pharmacology (12.2)].

10.2 Immediate Management

Immediate management of opioid overdose includes removal of the ABSTRAL tablet, if still in the mouth, ensuring a patent airway, physical and verbal stimulation of the patient, and assessment of level of consciousness, ventilatory and circulatory status.

10.3 Treatment of Overdosage (Accidental Ingestion) in the Opioid NON-Tolerant Person

Provide ventilatory support, obtain intravenous access, and administer naloxone or other opioid antagonists as clinically indicated. The duration of respiratory depression following overdose may be longer than the effects of the opioid antagonist's action (e.g., the half-life of naloxone ranges from 30 to 81 minutes) and repeated administration may be necessary. Consult the package insert of the individual opioid antagonist for details.

10.4 Treatment of Overdosage in Opioid-Tolerant Patients

Provide ventilatory support and obtain intravenous access as clinically indicated. Judicious use of naloxone or another opioid antagonist may be warranted in some instances, but at the risk of precipitating an acute withdrawal syndrome.

10.5 General Considerations for Overdose

Management of severe ABSTRAL overdose includes: securing a patent airway, assisting or controlling ventilation and establishing intravenous access. In the presence of hypoventilation or apnea, assist or control ventilation, and administer oxygen as indicated.

Carefully observe and appropriately manage patients with overdose until their clinical condition is well controlled.

Although muscle rigidity interfering with respiration has not been seen following the use of ABSTRAL, this is possible with fentanyl and other opioids. If it occurs, manage it by using assisted or controlled ventilation, by an opioid antagonist, and as a final alternative, by a neuromuscular blocking agent.

---

### Evolution of anti-B cell therapeutics in autoimmune neurological diseases [^116YLTgE]. Neurotherapeutics (2022). Medium credibility.

Stiff-Person Syndrome and Progressive Encephalomyelitis with Rigidity and Myoclonus

In stiff-person syndrome (SPS) and SPS-spectrum disorders (SPS-SD) as well as patients with progressive encephalomyelitis with rigidity and myoclonus (PERM), B cell involvement is supported by the presence of seemingly nonpathogenic antibodies against glutamic acid decarboxylase, an intracellular antigen, or by the likely pathogenic antibodies against the glycine receptor. In addition, both memory B cells and bone marrow plasma cells specific for GAD have been shown to be present in patients with SPS and have the ability to produce GAD antibodies upon non-specific stimulation (memory cells) but also without stimulation (plasma cells). Case reports have provided evidence that rituximab can help patients with stiff-person syndrome. In the largest controlled study we have conducted, however, rituximab was not statistically effective because of a strong placebo effect but 35% of patients clinically improved and some of them with impressive benefits. Rituximab still remains a treatment option in SPS patients unresponsive to IVIg; further, in a recent case series, rituximab improved some SPS patients. Rituximab has been also effective in a glycine receptor antibody-positive PERM patient of ours. This patient, hospitalized in the ICU for 12 months, requiring mechanical ventilation and being IVIg-unresponsive, impressively improved after rituximab infusion to the point of being able to walk and be discharged; interestingly, improvement was associated with significant reduction of the glycine receptor antibodies in his serum and disappearance from the CSF.

---

### Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee [^116vT4tw]. Muscle & Nerve (2009). Medium credibility.

Stiff-person syndrome (SPS) — efficacy of intravenous immunoglobulin (IVIG): There is one Class I study evaluating the use of IVIG in SPS; in a double-blinded crossover trial, patients were randomized to IVIG 2 g/kg over 2 consecutive days or placebo for 3 mo, and those receiving IVIG had improvement in reduced stiffness (p = .01) and sensitivity to spasms (p = .03) compared to placebo, with 11 of 16 patients improving in gait and activities of daily living. A retrospective study of maintenance IVIG reported long-term effectiveness in 36 patients with SPS over a 40 mo period, with Twenty-four of 36 (67%) patients showing a beneficial response; based on one Class I study, IVIG is effective in treating SPS.

---

### Fentanyl citrate (abstral) [^1111rY25]. FDA (2014). Low credibility.

10 OVERDOSAGE

10.1 Clinical Presentation

The manifestations of ABSTRAL overdosage are expected to be similar in nature to intravenous fentanyl and other opioids, and are an extension of its pharmacological actions with the most serious significant effect being hypoventilation [see Clinical Pharmacology (12.2)].

10.2 Immediate Management

Immediate management of opioid overdose includes removal of the ABSTRAL tablet, if still in the mouth, ensuring a patent airway, physical and verbal stimulation of the patient, and assessment of level of consciousness, ventilatory and circulatory status.

10.3 Treatment of Overdosage (Accidental Ingestion) in the Opioid NON-Tolerant Person

Provide ventilatory support, obtain intravenous access, and administer naloxone or other opioid antagonists as clinically indicated. The duration of respiratory depression following overdose may be longer than the effects of the opioid antagonist's action (e.g., the half-life of naloxone ranges from 30 to 81 minutes) and repeated administration may be necessary. Consult the package insert of the individual opioid antagonist for details.

10.4 Treatment of Overdosage in Opioid-Tolerant Patients

Provide ventilatory support and obtain intravenous access as clinically indicated. Judicious use of naloxone or another opioid antagonist may be warranted in some instances, but at the risk of precipitating an acute withdrawal syndrome.

10.5 General Considerations for Overdose

Management of severe ABSTRAL overdose includes: securing a patent airway, assisting or controlling ventilation and establishing intravenous access. In the presence of hypoventilation or apnea, assist or control ventilation, and administer oxygen as indicated.

Carefully observe and appropriately manage patients with overdose until their clinical condition is well controlled.

Although muscle rigidity interfering with respiration has not been seen following the use of ABSTRAL, this is possible with fentanyl and other opioids. If it occurs, manage it by using assisted or controlled ventilation, by an opioid antagonist, and as a final alternative, by a neuromuscular blocking agent.

---

### Evaluation and management of obstructive sleep apnea in adults hospitalized for medical care: an American Academy of Sleep Medicine clinical practice guideline [^1141UP8k]. Journal of Clinical Sleep Medicine (2025). High credibility.

American Academy of Sleep Medicine (AASM) clinical practice guidelines — implications of strong recommendations ("We Recommend… ") versus conditional recommendations ("We Suggest… ") are delineated for clinicians, patients, and policy makers. For clinicians under strong recommendations, "Almost all patients should be offered the recommended course of action. Adherence to this recommendation could be used as a quality criterion or performance indicator". Under conditional recommendations, "Most patients should be offered the suggested course of action; however, different choices may be appropriate for different patients. The clinician must help each patient determine if the suggested course of action is clinically appropriate and consistent with their values and preferences". For patients under strong recommendations, "Almost all patients should be offered the recommended course of action, although a small proportion of patients would not choose it". Under conditional recommendations, "Most patients should be offered the suggested course of action, though some may not choose it. Different choices may be appropriate for different patients. The patient should work with their clinician to determine if the suggested course of action is clinically appropriate and consistent with their values and preferences". For policy makers under strong recommendations, "The recommended course of action can be adopted as policy for most situations. Adherence to the recommended course of action could be used as a quality criterion or performance indicator". Under conditional recommendations, "The ultimate judgment regarding the suitability of the suggested course of action must be made by the clinician and patient together, based on what is best for the patient. This decision-making flexibility should be accounted for when establishing policies".

---

### Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology [^1169ETd7]. Brain (2018). Low credibility.

Stiff person spectrum disorders and acquired hyperekplexia

SPSD are characterized by the core symptoms of fluctuating muscle stiffness with superimposed spasms, and an exaggerated startle response (hyperekplexia). The manifestations include classical stiff person syndrome, stiff limb syndrome, and variants combined with additional neurological symptoms (stiff person plus) or with a potentially fatal disease course in progressive encephalomyelitis with rigidity and myoclonus (PERM). Acquired hyperekplexia also enters this spectrum of disorders. In practice, SPSDs are still often misdiagnosed and symptoms mistaken for psychogenic, dystonic posturing, or related to parkinsonism. Nevertheless, stiffness and spasms can cause significant morbidity with falls, fractures, or even death due to respiratory failure.

The most frequent antibodies remain those against GAD and the glycine receptor (GlyR), and less frequently, amphiphysin. The antibody spectrum associated with SPSD has expanded with recent reports of DPPX, GABA A R and GlyT2 antibodies, but further work is needed to elucidate each of their roles in SPSD. Overall, it is difficult to predict the antibody specificity based on clinical grounds, as there is significant overlap between the various antibodies with regard phenotype and disease course. However, patients with GAD antibodies often also have cerebellar ataxia and, less frequently, temporal lobe epilepsy. Myelopathy and sensory neuropathy, in association with SPSD strongly indicate a paraneoplastic syndrome with amphiphysin antibodies.

GlyR antibodies associate with prominent brainstem involvement including oculomotor or bulbar disturbance, myoclonus and hyperekplexia, and often sensory and autonomic symptoms. Patients with DPPX antibodies tend to have trunk stiffness, prominent cerebellar ataxia and striking hyperekplexia, together with various degrees of dysautonomia, somatosensory disturbances, and cognitive decline. Gastrointestinal hyper- or hypomobility and marked weight loss are strong indicators of DPPX antibodies.

---

### Miller fisher syndrome and COVID-19: is there a link? [^111qACcg]. BMJ Case Reports (2020). High credibility.

Beyond the typical respiratory symptoms and fever associated with severe acute respiratory syndrome, we may still have much to learn about other manifestations of the novel SARS-CoV-2 infection. A patient presented with Guillain-Barré syndrome in China with a concurrent SARS-CoV-2 infection. The following case report looks at a patient presenting with the rare Miller Fisher syndrome, a variant of Guillain-Barré while also testing positive for COVID-19.

---

### Brief resolved unexplained events (formerly apparent life-threatening events) and evaluation of lower-risk infants [^114EQub4]. Pediatrics (2016). Medium credibility.

Guideline definitions for key action statements (Table 4) — a strong recommendation is defined as "A particular action is favored because anticipated benefits clearly exceed harms (or vice versa) and quality of evidence is excellent or unobtainable", with the implication "Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present". A moderate recommendation is defined as "A particular action is favored because anticipated benefits clearly exceed harms (or vice versa) and the quality of evidence is good but not excellent (or is unobtainable)", implying "Clinicians would be prudent to follow a moderate recommendation but should remain alert to new information and sensitive to patient preferences". A weak recommendation (based on low-quality evidence) is defined as "A particular action is favored because anticipated benefits clearly exceed harms (or vice versa), but the quality of evidence is weak", with the implication "Clinicians would be prudent to follow a weak recommendation but should remain alert to new information and very sensitive to patient preferences". A weak recommendation (based on balance of benefits and harms) is defined as "Weak recommendation is provided when the aggregate database shows evidence of both benefit and harm that appear to be similar in magnitude for any available courses of action", implying "Clinicians should consider the options in their decision-making, but patient preference may have a substantial role".

---

### Core diagnostic features of stiff person syndrome: insights from a case-control study [^116TQUZn]. Journal of Neurology (2025). Medium credibility.

Background

Stiff person syndrome spectrum disorders (SPSD) are rare, disabling neuroimmunological conditions with no consensus diagnostic criteria, making diagnosis challenging. Misdiagnosis often occurs due to the limited awareness of atypical symptoms and presentations. This study aimed to identify key clinical and paraclinical features most predictive of classic SPS and SPS-plus diagnosis and misdiagnosis patterns.

Methods

We conducted a retrospective case-control study at Johns Hopkins SPS center, analyzing patient data from 1997–2021. A total of 154 classic SPS, 45 SPS-plus, and 66 control patients (evaluated for SPSD but given an alternative diagnosis) were included. Clinical assessments, autoantibody testing, electromyography (EMG), and other diagnostic studies were reviewed. Sensitivity, specificity, and diagnostic odds ratios were calculated, with logistic regression identifying the strongest diagnostic indicators of the SPS phenotypes.

Results

Torso/lower extremity symptoms, hypersensitivity triggers, paravertebral stiffness, and gait dysfunction were common in both phenotypes. Classic SPS was most specifically associated with high-titer GAD65 antibodies (98%), cerebrospinal fluid GAD65 positivity (100%), characteristic EMG abnormalities (> 90%), and hyperlordosis (87%). SPS-plus specificity was highest for cerebellar (98.5%) and brainstem (100%) signs/symptoms. High-titer GAD65 antibodies were the strongest independent diagnostic factor for both phenotypes. Misdiagnosis was most common in patients presenting with upper extremity, brainstem, or cerebellar involvement.

Conclusions

Recognizing key diagnostic and misdiagnosis patterns may help clinicians make accurate and timely diagnoses of SPSD. This could help prevent misdiagnosis/overdiagnosis, ensure timely treatment, and assure appropriate patient populations are included in future interventional SPS clinical trials. Further studies are needed to validate these findings and refine diagnostic criteria.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00415-025-13103-2.

---

### British thoracic society guidelines for home oxygen use in adults [^111fwC1j]. Thorax (2015). Medium credibility.

Regarding specific circumstances for home oxygen, more specifically with respect to patients with obstructive sleep apnea, BTS 2015 guidelines recommend to combine oxygen with noninvasive ventilatory support in patients with evidence of established ventilatory failure in whom oxygen is indicated.

---

### Stiff-person syndrome and GAD antibody-spectrum disorders: GABAergic neuronal excitability, immunopathogenesis and update on antibody therapies [^115FqHYv]. Neurotherapeutics (2022). Medium credibility.

Hyperexcitability of the Motor Cortex, Brain Imaging and Reduction in Brain GABA

To substantiate that impaired GABAergic inhibitory transmission results in cortical hyperexcitability leading to muscle rigidity and spasms, we measured brain GABA and assessed electrophysiologically intracortical inhibition and excitation. Brain MRI imaging is normal in SPS and SPS-SD, but magnetic resonance spectroscopy studies have shown prominent and significant reduction in GABA predominantly in the sensorimotor cortex and to a lesser degree in the posterior occipital cortex, indicating involvement of the inhibitory GABAergic pathways. The reduced brain GABA is also supported by concomitantly finding reduced GABA levels in the cerebrospinal fluid, as mentioned earlier.

To determine if GABA reduction in the sensorimotor cortex is associated with dysfunction of supraspinal GABAergic neurons, we performed transcranial magnetic stimulation studies to assess intracortical inhibition and excitation. SPS patients had decreased inhibition and markedly increased facilitation at short intervals pointing to motor cortex hyperexcitability owing to impaired supraspinal GABA-ergic neurons that lead to imbalance between inhibitory and excitatory intracortical circuitry. Such diffuse motor cortex hyperexcitability can produce an excessive corticospinal response upon activation explaining the stimuli-induced muscle spasms seen in SPS. These findings were further supported by the blink reflex studies which showed that the recovery cycle of the R2 component was enhanced in SPS patients compared to controls, indicative of hyperexcitability of brainstem interneuronal circuits due to loss of inhibitory interneurons reflecting a widespread dysfunction of central inhibitory pathways.

---

### Stiff-person syndrome and GAD antibody-spectrum disorders: GABAergic neuronal excitability, immunopathogenesis and update on antibody therapies [^115evNVs]. Neurotherapeutics (2022). Medium credibility.

Although antibodies against Glutamic Acid Decarboxylase (GAD) were originally associated with Stiff Person Syndrome (SPS), they now denote the "GAD antibody-spectrum disorders (GAD-SD)" that include Cerebellar Ataxia, Autoimmune Epilepsy, Limbic Encephalitis, PERM and eye movement disorder. In spite of the unique clinical phenotype that each of these disorders has, there is significant overlapping symptomatology characterized by autoimmune neuronal excitability. In addition to GAD, three other autoantibodies, against glycine receptors, amphiphysin and gephyrin, are less frequently or rarely associated with SPS-SD. Very high serum anti-GAD antibody titers are a key diagnostic feature for all GAD-SD, commonly associated with the presence of GAD antibodies in the CSF, a reduced CSF GABA level and increased anti-GAD-specific IgG intrathecal synthesis denoting stimulation of B-cell clones in the CNS. Because anti-GAD antibodies from the various hyperexcitability syndromes recognize the same dominant GAD epitope, the clinical heterogeneity among GAD-SD patients remains unexplained. The paper highlights the biologic basis of autoimmune hyperexcitability connected with the phenomenon of reciprocal inhibition as the fundamental mechanism of the patients' muscle stiffness and spasms; addresses the importance of high-GAD antibody titers in diagnosis, pinpointing the diagnostic challenges in patients with low-GAD titers or their distinction from functional disorders; and discusses whether high GAD-antibodies are disease markers or pathogenic in the context of their association with reduced GABA level in the brain and CSF. Finally, it focuses on therapies providing details on symptomatic GABA-enhancing drugs and the currently available immunotherapies in a step-by-step approach. The prospects of future immunotherapeutic options with antibody therapies are also summarized.

Supplementary Information

The online version contains supplementary material available at 10.1007/s13311-022-01188-w.

---

### An update on the diagnosis and treatment of parkinson disease [^1113h86w]. CMAJ (2016). Low credibility.

The following constitutes key background information on Parkinson's disease:

- **Definition**: PD is a chronic neurodegenerative disorder characterized by motor, cognitive and autonomic dysfunction, as well as mood and impulse control disorders.
- **Pathophysiology**: The exact cause of PD is unknown; however, a combination of genetic and environmental factors have been implicated. Advancing age (> 65 years), male gender, genetics (LRRK2, glucocerebrosidase, and Parkin mutation), industrial exposure, heavy metals (manganese, copper, and lead), pesticides (rotenone, paraquat), and obstructive sleep apnea increase the risk of PD.
- **Epidemiology**: The incidence of PD in the US is estimated at 9.5–10.3 cases per 100,000 person-years, while its prevalence is estimated at 81 persons per 100,000 population.
- **Disease course**: In patients with PD, premature selective loss of dopamine neurons and accumulation of Lewy bodies causes the classical motor manifestations of parkinsonism (tremor, rigidity, bradykinesia, and postural instability), as well as autonomic dysfunction, cognitive dysfunction, and mood and impulse control disorders.
- **Prognosis and risk of recurrence**: Patients with PD have 2.56-fold increased risk of mortality than similar age-matched individuals.

---

### Stiff-person syndrome… [^111XX5Xc]. Wikipedia (2005). Low credibility.

Stiff-person syndrome, also known as stiff-man syndrome, is a rare neurological disorder of unclear cause characterized by progressive muscular rigidity and stiffness. The stiffness primarily affects the truncal muscles and is characterised by spasms, resulting in postural deformities. Chronic pain, impaired mobility, and lumbar hyperlordosis are common symptoms. SPS was first described in 1956. Diagnostic criteria were proposed in the 1960s and refined two decades later. In the 1990s and 2000s, the role of antibodies in the condition became clearer. SPS patients generally have glutamic acid decarboxylase antibodies, which seldom occur in the general population. In addition to blood tests for GAD, electromyography tests can help confirm the condition's presence. Benzodiazepine-class drugs are the most common treatment; they are used for symptom relief from stiffness. Other common treatments include baclofen, intravenous immunoglobin, and rituximab.

Limited but encouraging therapeutic experience of haematopoietic stem cell transplantation exists for SPS. Signs and symptoms Stiff-person syndrome is often separated into several subtypes, based on the cause and progression of the disease. There are three clinical classifications of SPS:
- Classic SPS, associated with other autoimmune conditions and usually GAD-positive
- Partial SPS variants
- Progressive encephalomyelitis with rigidity and myoclonus. Around 70% of those with SPS have the "classic" form of the disease. People with classic SPS typically first experience intermittent tightness or aching in the muscles of the trunk. These muscles repeatedly and involuntarily contract, causing them to grow and rigidify. Eventually, rigidified muscles reduce the affected person's range of motion, slow their voluntary movements, and may cause them to have abnormal posture, particularly lumbar hyperlordosis.

Rigid trunk muscles can also prevent the chest and abdomen from expanding, causing shortness of breath and early satiety. In many people with SPS, muscle rigidity eventually progresses from the trunk to the limbs — first affecting muscles closest to the trunk, then further. Stiffened limbs can affect a person's balance and gait, causing awkward 'statue-like' falls, where the affected person cannot put out their arms to soften the impact. Alongside growing stiffness, many with SPS develop bouts of muscle spasms that are triggered by sudden movements and feeling upset or startled. Spasms are sometimes accompanied by elevated blood pressure, heart rate, body temperature, and sweating. Some experience chronic muscle pain. The muscle stiffness initially fluctuates, sometimes for days or weeks, but eventually begins to consistently impair mobility. As the disease progresses, patients sometimes become unable to walk or bend.

Chronic pain is common and worsens over time, but sometimes acute pain occurs as well. Stress, cold weather, and infections lead to an increase in symptoms, and sleep decreases them. Causes Patients with SPS generally have high glutamic acid decarboxylase antibody levels in their blood. About 80% of SPS patients have GAD antibodies, compared with about 1% of the general population. The overwhelming majority of people who have GAD antibodies do not develop SPS, indicating that systemic synthesis of the antibody is not the sole cause of SPS. GAD, a presynaptic autoantigen, is generally thought to play a key role in the condition, but exact details of the way autoantibodies affect SPS patients are not known. Most SPS patients with high-titer GAD antibodies also have antibodies that inhibit GABA-receptor-associated protein. In SPS patients, motor-unit neurons fire involuntarily in a way that resembles a normal contraction.

---

### Stiff-person syndrome [^115YEdeU]. Wikipedia (2005). Low credibility.

Stiff-person syndrome, also known as stiff-man syndrome, is a rare neurological disorder of unclear cause characterized by progressive muscular rigidity and stiffness. The stiffness primarily affects the truncal muscles and is characterised by spasms, resulting in postural deformities. Chronic pain, impaired mobility, and lumbar hyperlordosis are common symptoms. SPS was first described in 1956. Diagnostic criteria were proposed in the 1960s and refined two decades later. In the 1990s and 2000s, the role of antibodies in the condition became clearer. SPS patients generally have glutamic acid decarboxylase antibodies, which seldom occur in the general population. In addition to blood tests for GAD, electromyography tests can help confirm the condition's presence. Benzodiazepine-class drugs are the most common treatment; they are used for symptom relief from stiffness. Other common treatments include baclofen, intravenous immunoglobin, and rituximab.

Limited but encouraging therapeutic experience of haematopoietic stem cell transplantation exists for SPS. Signs and symptoms Stiff-person syndrome is often separated into several subtypes, based on the cause and progression of the disease. There are three clinical classifications of SPS:
- Classic SPS, associated with other autoimmune conditions and usually GAD-positive
- Partial SPS variants
- Progressive encephalomyelitis with rigidity and myoclonus. Around 70% of those with SPS have the "classic" form of the disease. People with classic SPS typically first experience intermittent tightness or aching in the muscles of the trunk. These muscles repeatedly and involuntarily contract, causing them to grow and rigidify. Eventually, rigidified muscles reduce the affected person's range of motion, slow their voluntary movements, and may cause them to have abnormal posture, particularly lumbar hyperlordosis.

Rigid trunk muscles can also prevent the chest and abdomen from expanding, causing shortness of breath and early satiety. In many people with SPS, muscle rigidity eventually progresses from the trunk to the limbs — first affecting muscles closest to the trunk, then further. Stiffened limbs can affect a person's balance and gait, causing awkward 'statue-like' falls, where the affected person cannot put out their arms to soften the impact. Alongside growing stiffness, many with SPS develop bouts of muscle spasms that are triggered by sudden movements and feeling upset or startled. Spasms are sometimes accompanied by elevated blood pressure, heart rate, body temperature, and sweating. Some experience chronic muscle pain. The muscle stiffness initially fluctuates, sometimes for days or weeks, but eventually begins to consistently impair mobility. As the disease progresses, patients sometimes become unable to walk or bend.

Chronic pain is common and worsens over time, but sometimes acute pain occurs as well. Stress, cold weather, and infections lead to an increase in symptoms, and sleep decreases them. Causes Patients with SPS generally have high glutamic acid decarboxylase antibody levels in their blood. About 80% of SPS patients have GAD antibodies, compared with about 1% of the general population. The overwhelming majority of people who have GAD antibodies do not develop SPS, indicating that systemic synthesis of the antibody is not the sole cause of SPS. GAD, a presynaptic autoantigen, is generally thought to play a key role in the condition, but exact details of the way autoantibodies affect SPS patients are not known. Most SPS patients with high-titer GAD antibodies also have antibodies that inhibit GABA-receptor-associated protein. In SPS patients, motor-unit neurons fire involuntarily in a way that resembles a normal contraction.

---

### Portal: COVID-19… [^116aj3Ap]. Wikipedia (2025). Medium credibility.

Several COVID-19 vaccines have been approved and distributed in various countries, many of which have initiated mass vaccination campaigns. Other preventive measures include physical or social distancing, quarantining, ventilation of indoor spaces, use of face masks or coverings in public, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. While drugs have been developed to inhibit the virus, the primary treatment is still symptomatic, managing the disease through supportive care, isolation, and experimental measures. million estimated deaths. The pandemic ranks as the fifth-deadliest pandemic or epidemic in history. SARS-CoV-2 is the seventh known coronavirus to infect people, after 229E, NL63, OC43, HKU1, MERS-CoV, and the original SARS-CoV. About the symptoms The symptoms of COVID-19 are variable depending on the type of variant contracted, ranging from mild symptoms to a potentially fatal illness.

Common symptoms include coughing, fever, loss of smell and taste, with less common ones including headaches, nasal congestion and runny nose, muscle pain, sore throat, diarrhea, eye irritation, and toes swelling or turning purple, and in moderate to severe cases, breathing difficulties. People with the COVID-19 infection may have different symptoms, and their symptoms may change over time. Infectious particles range in size from aerosols that remain suspended in the air for long periods of time to larger droplets that remain airborne briefly or fall to the ground. Additionally, COVID-19 research has redefined the traditional understanding of how respiratory viruses are transmitted. The largest droplets of respiratory fluid do not travel far, but can be inhaled or land on mucous membranes on the eyes, nose, or mouth to infect.

Aerosols are highest in concentration when people are in close proximity, which leads to easier viral transmission when people are physically close, but airborne transmission can occur at longer distances, mainly in locations that are poorly ventilated; in those conditions small particles can remain suspended in the air for minutes to hours. Containment measures Many countries attempted to slow or stop the spread of COVID-19 by recommending, mandating or prohibiting behaviour changes, while others relied primarily on providing information. Measures ranged from public advisories to stringent lockdowns. Outbreak control strategies are divided into elimination and mitigation. Experts differentiate between" zero-COVID", which is an elimination strategy, and mitigation strategies that attempt to lessen the effects of the virus on society, but which still tolerate some level of transmission within the community.

Containment strategies consists of the use of public health measures such as contact tracing, mass testing, border quarantine, lockdowns and mitigation software. These strategies can be pursued sequentially or simultaneously during the acquired immunity phase through natural and vaccine-induced immunity. Videos
- Animation describing the structure of a coronavirus
- Video about what SARS-CoV-2 does to the human body
- Video about the transmission of coronaviruses. Recent news
- 19 September 2025 – COVID-19 in the United States The United States Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices unanimously votes to abandon its recommendation for the COVID-19 vaccine and now recommends that Americans get the vaccine based on their personal choice. In a separate vote, the committee votes for the CDC to communicate clear risks about COVID-19 vaccines. Did you know.

---

### Long COVID… [^111MUbGb]. Wikipedia (2020). Medium credibility.

Long COVID is characterised by a large number of symptoms that sometimes disappear and then reappear. Commonly reported symptoms of long COVID are fatigue, memory problems, shortness of breath, and sleep disorder. Several other symptoms, including headaches, mental health issues, initial loss of smell or taste, muscle weakness, fever, and cognitive dysfunction may also present. Symptoms often get worse after mental or physical effort, a process called post-exertional malaise. There is a large overlap in symptoms with myalgic encephalomyelitis/chronic fatigue syndrome. The causes of long COVID are not yet fully understood. Hypotheses include lasting damage to organs and blood vessels, problems with blood clotting, neurological dysfunction, persistent virus or a reactivation of latent viruses and autoimmunity. Diagnosis of long COVID is based on COVID-19 infection or symptoms — and by excluding alternative diagnoses.

Management of long COVID depends on symptoms. Rest is recommended for fatigue and pacing for post-exertional malaise. People with severe symptoms or those who were in intensive care may require care from a team of specialists. Most people with symptoms at 4 weeks recover by 12 weeks. Recovery is slower for those still ill at 12 weeks. For a subset of people, for instance those meeting the criteria for ME/CFS, symptoms are expected to be lifelong. Long COVID has many symptoms in common with myalgic encephalomyelitis/chronic fatigue syndrome and research estimates half of people with long COVID meet ME/CFS diagnostic criteria. Like long COVID, ME/CFS is often triggered by infections, and some biological changes overlap. Dysautonomia and postural orthostatic tachycardia syndrome are also potential shared aspects of long COVID and ME/CFS. However, long COVID symptoms include loss of smell and taste, neither of which feature frequently in ME/CFS.

Some people with long COVID experience dysautonomia, a malfunction of the autonomic nervous system. People with dysautonomia may experience palpitations and tachycardia after minor effort or upon standing up. This can be associated with dizziness and nausea. If the heart rate is raised by 30 beats per minute or more after continuous standing; this is described as postural orthostatic tachycardia syndrome. In the cardiovascular system, effort intolerance and chest pain occur often in people with long COVID. Sufferers of Long COVId are also at increased risks of developing strokes, myocarditis, the postural orthostatic tachycardia syndrome, pulmonary embolisms, deep vein thrombosis, and myocardial infarction. Subgroups Because the symptom combinations of long COVID vary significantly from person to person, one approach to researching the condition is to define subgroups or clusters of long-haulers. This would allow for more targeted clinical care. Causes and mechanisms The causes of long COVID are not yet fully understood. It is likely that there is no single cause, but instead multiple, and possibly overlapping, mechanisms that all contribute to the development of long COVID. Organ damage from the acute infection can explain a part of the symptoms, but long COVID is also observed in people where organ damage seems to be absent. Several hypotheses have been put forward explaining long COVID, including:

---

### Hypercapnia… [^111aPaGY]. Wikipedia (2004). Low credibility.

Acute hypercapnia is called acute hypercapnic respiratory failure and is a medical emergency as it generally occurs in the context of acute illness. Chronic hypercapnia, where metabolic compensation is usually present, may cause symptoms but is not generally an emergency. Depending on the scenario both forms of hypercapnia may be treated with medication, with mask-based non-invasive ventilation or with mechanical ventilation. The risk of dangerous irregularities of the heart beat is increased. Hypercapnia also occurs when the breathing gas is contaminated with carbon dioxide, or respiratory gas exchange cannot keep up with the metabolic production of carbon dioxide, which can occur when gas density limits ventilation at high ambient pressures. In severe hypercapnia greater than 10 kPa or 75 mmHg), symptomatology progresses to disorientation, panic, hyperventilation, convulsions, unconsciousness, and eventually death.

Causes Carbon dioxide is a normal metabolic product but it accumulates in the body if it is produced faster than it is cleared. During strenuous exercise the production rate of carbon dioxide can increase more than tenfold over the production rate during rest. Carbon dioxide is dissolved in the blood and elimination is by gas exchange in the lungs during breathing. Acute hypercapnic respiratory failure may occur in acute illness caused by chronic obstructive pulmonary disease, chest wall deformity, some forms of neuromuscular disease, and obesity hypoventilation syndrome. AHRF may also develop in any form of respiratory failure where the breathing muscles become exhausted, such as severe pneumonia and acute severe asthma. It can also be a consequence of profound suppression of consciousness such as opioid overdose.
- Increased work of breathing accounted for most of the elevation of \ in exposures above 1 atm, as indicated by the results when helium was substituted for nitrogen at 4 atm.
- Inadequate ventilatory response to exertion was indicated by the fact that, despite resting values in the normal range, \ rose markedly with exertion even when the divers breathed air at a depth of only a few feet.
- The diver is overexercising, producing excess carbon dioxide due to elevated metabolic activity and respiratory gas exchange cannot keep up with the metabolic production of carbon dioxide.
- Gas density limits ventilation at high ambient pressures. The density of the breathing gas is higher at depth, so the effort required to fully inhale and exhale increases, making breathing more difficult and less efficient.

Higher gas density also causes gas mixing within the lung to be less efficient, thus increasing the effective dead space.
- The diver is deliberately hypoventilating, known as "skip breathing". Hypercapnia can induce increased cardiac output, an elevation in arterial blood pressure, and a propensity toward cardiac arrhythmias. Hypercapnia may increase pulmonary capillary resistance. Physiological effects A high arterial partial pressure of carbon dioxide) causes changes in brain activity that adversely affect both fine muscular control and reasoning. EEG changes denoting minor narcotic effects can be detected for expired gas end tidal partial pressure of carbon dioxide) increase from 40 torrs to approximately 50 torrs.

---

### COVID-19 pandemic [^116LzvmX]. Wikipedia (2020). Medium credibility.

Treatments include novel antiviral drugs and symptom control. Common mitigation measures during the public health emergency included travel restrictions, lockdowns, business restrictions and closures, workplace hazard controls, mask mandates, quarantines, testing systems, and contact tracing of the infected. Official death counts have been claimed to underreport the actual death toll, because excess mortality data show an increase in deaths that is not explained by COVID-19 deaths alone. Such deaths include deaths due to healthcare capacity constraints and priorities, as well as reluctance to seek care. Further research may help distinguish the proportions directly caused by COVID-19 from those caused by indirect consequences of the pandemic. A December 2022 WHO study estimated excess deaths from the pandemic during 2020 and 2021, again concluding ≈14.

8 million excess early deaths occurred, reaffirming and detailing their prior calculations from May as well as updating them, addressing criticisms. These numbers do not include measures like years of potential life lost and may make the pandemic 2021's leading cause of death. In November 2020, a review article in Nature reported estimates of population-weighted IFRs for various countries, excluding deaths in elderly care facilities, and found a median range of 0. 24% to

1. 49%. IFRs rise as a function of age. These rates vary by a factor of ≈10, 000 across the age groups. For comparison, the IFR for middle-aged adults is two orders of magnitude higher than the annualised risk of a fatal automobile accident and much higher than the risk of dying from seasonal influenza.

In December 2020, a systematic review and meta-analysis estimated that population-weighted IFR was 0. 5% to 1% in some countries, 1% to 2% in other countries, and about
2. 5% in Italy. This study reported that most of the differences reflected corresponding differences in the population's age structure and the age-specific pattern of infections. There have also been reviews that have compared the fatality rate of this pandemic with prior pandemics, such as MERS-CoV. Three common clusters of symptoms have been identified: one respiratory symptom cluster with cough, sputum, shortness of breath, and fever; a musculoskeletal symptom cluster with muscle and joint pain, headache, and fatigue; a cluster of digestive symptoms with abdominal pain, vomiting, and diarrhoea.

In people without prior ear, nose, and throat disorders, loss of taste combined with loss of smell is associated with COVID-19 and is reported in as many as 88% of cases. Human coronaviruses are capable of causing illnesses ranging from the common cold to more severe diseases such as Middle East respiratory syndrome. SARS-CoV-2 is the seventh known coronavirus to infect people, after 229E, NL63, OC43, HKU1, MERS-CoV, and the original SARS-CoV. Vaccines A COVID-19 vaccine is intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2, the virus that causes coronavirus disease 2019. Prior to the COVID-19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome and Middle East respiratory syndrome.